


BB



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 761 669 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication
12.03.1997 Bulletin 1997/11

(51) Int Cl 6 C07D 495/04, C07D 311/78,

C07D 221/18, C07D 493/04,
A61K 31/35, A61K 31/435,
C07F 7/18

(21) Application number 96306351.6

// (C07D495/04, 333:00,
311:00),
(C07D493/04, 311:00, 307:00)

(22) Date of filing 02.09.1996

(84) Designated Contracting States
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE

Designated Extension States:
AL LT LV SI

(30) Priority: 08.09.1995 US 3496


(71) Applicant ELI LILLY AND COMPANY
Indianapolis, Indiana 46285 (US)

(72) Inventor: Grese, Timothy Alan
Indianapolis, Indiana 46236 (US)


(74) Representative: Tapping, Kenneth George et al
Lilly Industries Limited
European Patent Operations
Erl Wood Manor
Windlesham Surrey GU20 6PH (GB)

(54) Pentacyclic compounds, intermediates, processes, compositions, and methods

(57) The present invention relates to compounds of formula I and II,



EP 0 761 669 A2



wherein

X is -O-, -S-, or -NR⁵-;

Y is -O-, -S-, -CH₂-, -CH₂CH₂-, -CH=CH-, or -NR⁵-;

B is -CH²- or -CO-

R¹, R², and R³ are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₄-C₆ alkyl), -OSO₂CF₃, Cl, or F;

n is 1 or 2,

W is CH₂ or C=O,

R⁴ is 1-piperidinyl, 2-oxo-1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino.

R⁵ is C₁-C₃ alkyl, -COC₆H₅, -CO(C₁-C₆ alkyl), -C(O)OC₆H₅, -C(O)O(C₁-C₆ alkyl), -SO₂(C₁-C₆ alkyl), -SO₂C₆H₅, or -SO₂CF₃;

or a pharmaceutically acceptable salt thereof

Also provided by the present invention are intermediate compounds; processes for the preparation of compounds of Formulae I and II; and pharmaceutical methods and formulations employing the compounds of Formulae I and II

Description

This invention relates to the fields of pharmaceutical and organic chemistry and provides novel pentacyclic compounds which are useful for the treatment of the various medical indications associated with post-menopausal syndrome, and uterine fibroid disease, endometriosis, and aortal smooth muscle cell proliferation. The present invention further relates to intermediate compounds and processes useful for preparing the pharmaceutically active compounds of the present invention, and pharmaceutical compositions.

"Post-menopausal syndrome" is a term used to describe various pathological conditions which frequently affect women who have entered into or completed the physiological metamorphosis known as menopause. Although numerous pathologies are contemplated by the use of this term, three major effects of post-menopausal syndrome are the source of the greatest long-term medical concern: osteoporosis, cardiovascular effects such as hyperlipidemia, and estrogen-dependent cancer, particularly breast and uterine cancer.

Osteoporosis describes a group of diseases which arise from diverse etiologies, but which are characterized by the net loss of bone mass per unit volume. The consequence of this loss of bone mass and resulting bone fracture is the failure of the skeleton to provide adequate structural support for the body. One of the most common types of osteoporosis is that associated with menopause. Most women lose from about 20% to about 60% of the bone mass in the trabecular compartment of the bone within 3 to 6 years after the cessation of menses. This rapid loss is generally associated with an increase of bone resorption and formation. However, the resorative cycle is more dominant and the result is a net loss of bone mass. Osteoporosis is a common and serious disease among post-menopausal women.

There are an estimated 25 million women in the United States, alone, who are afflicted with this disease. The results of osteoporosis are personally harmful and also account for a large economic loss due its chronicity and the need for extensive and long term support (hospitalization and nursing home care) from the disease sequelae. This is especially true in more elderly patients. Additionally, although osteoporosis is not generally thought of as a life threatening condition, a 20% to 30% mortality rate is related with hip fractures in elderly women. A large percentage of this mortality rate can be directly associated with post-menopausal osteoporosis.

The most vulnerable tissue in the bone to the effects of post-menopausal osteoporosis is the trabecular bone. This tissue is often referred to as spongy or cancellous bone and is particularly concentrated near the ends of the bone (near the joints) and in the vertebrae of the spine. The trabecular tissue is characterized by small osteoid structures which inter-connect with each other, as well as the more solid and dense cortical tissue which makes up the outer surface and central shaft of the bone. This inter-connected network of trabeculae gives lateral support to the outer cortical structure and is critical to the biomechanical strength of the overall structure. In post-menopausal osteoporosis, it is, primarily, the net resorption and loss of the trabeculae which leads to the failure and fracture of bone. In light of the loss of the trabeculae in post-menopausal women, it is not surprising that the most common fractures are those associated with bones which are highly dependent on trabecular support, e.g., the vertebrae, the neck of the weight bearing bones such as the femur and the fore-arm. Indeed, hip fracture, collar fractures, and vertebral crush fractures are hall-marks of post-menopausal osteoporosis.

At this time, the only generally accepted method for treatment of post-menopausal osteoporosis is estrogen replacement therapy. Although therapy is generally successful, patient compliance with the therapy is low primarily because estrogen treatment frequently produces undesirable side effects.

Throughout premenopausal time, most women have less incidence of cardiovascular disease than age-matched men. Following menopause, however, the rate of cardiovascular disease in women slowly increases to match the rate seen in men. This loss of protection has been linked to the loss of estrogen and, in particular, to the loss of estrogen's ability to regulate the levels of serum lipids. The nature of estrogen's ability to regulate serum lipids is not well understood, but evidence to date indicates that estrogen can upregulate the low density lipid (LDL) receptors in the liver to remove excess cholesterol. Additionally, estrogen appears to have some effect on the biosynthesis of cholesterol, and other beneficial effects on cardiovascular health.

It has been reported in the literature that post-menopausal women having estrogen replacement therapy have a return of serum lipid levels to concentrations to those of the pre-menopausal state. Thus, estrogen would appear to be a reasonable treatment for this condition. However, the side-effects of estrogen replacement therapy are not acceptable to many women, thus limiting the use of this therapy. An ideal therapy for this condition would be an agent which would regulate the serum lipid level as does estrogen, but would be devoid of the side-effects and risks associated with estrogen therapy.

The third major pathology associated with post-menopausal syndrome is estrogen-dependent breast cancer and, to a lesser extent, estrogen-dependent cancers of other organs, particularly the uterus. Although such neoplasms are not solely limited to a post-menopausal women, they are more prevalent in the older, post-menopausal population. Current chemotherapy of these cancers has relied heavily on the use of anti-estrogen compounds such as, for example, tamoxifen. Although such mixed agonist-antagonists have beneficial effects in the treatment of these cancers, and the estrogenic side-effects are tolerable in acute life-threatening situations, they are not ideal. For example, these agents

may have stimulatory effects on certain cancer cell populations in the uterus due to their estrogenic (agonist) properties and they may, therefore, be contraproductive in some cases. A better therapy for the treatment of these cancers would be an agent which is an anti-estrogen compound having negligible or no estrogen agonist properties on reproductive tissues

5 In response to the clear need for new pharmaceutical agents which are capable of alleviating the symptoms of, *inter alia*, post-menopausal syndrome, the present invention provides new pentacyclic compounds, pharmaceutical compositions thereof and methods of using such compounds for the treatment of post-menopausal syndrome and other estrogen-related pathological conditions such as those mentioned below

10 Uterine fibrosis (uterine fibroid disease) is an old and ever present clinical problem which goes under a variety of names, including uterine fibroid disease, uterine hypertrophy, uterine leiomyomata, myometrial hypertrophy, fibrosis uteri, and fibrotic metritis. Essentially, uterine fibrosis is a condition where there is an inappropriate deposition of fibroid tissue on the wall of the uterus

15 This condition is a cause of dysmenorrhea and infertility in women. The exact cause of this condition is poorly understood but evidence suggests that it is an inappropriate response of fibroid tissue to estrogen. Such a condition has been produced in rabbits by daily administrations of estrogen for 3 months. In guinea pigs, the condition has been produced by daily administration of estrogen for four months. Further in rats, estrogen causes similar hypertrophy

20 The most common treatment of uterine fibrosis involves surgical procedures both costly and sometimes a source of complications such as the formation of abdominal adhesions and infections. In some patients, initial surgery is only a temporary treatment and the fibroids regrow. In those cases a hysterectomy is performed which effectively ends the fibroids but also the reproductive life of the patient. Also, gonadotropin releasing hormone antagonists may be administered, yet their use is tempered by the fact they can lead to osteoporosis. Thus, there exists a need for new methods for treating uterine fibrosis, and the methods of the present invention satisfy that need.

25 Endometriosis is a condition of severe dysmenorrhea, which is accompanied by severe pain, bleeding into the endometrial masses or peritoneal cavity and often leads to infertility. The cause of the symptoms of this condition appear to be ectopic endometrial growths which respond inappropriately to normal hormonal control and are located in inappropriate tissues. Because of the inappropriate locations for endometrial growth, the tissue seems to initiate local inflammatory-like responses causing macrophage infiltration and a cascade of events leading to initiation of the painful response. The exact etiology of this disease is not well understood and its treatment by hormonal therapy is diverse, poorly defined, and marked by numerous unwanted and perhaps dangerous side effects

30 One of the treatments for this disease is the use of low dose estrogen to suppress endometrial growth through a negative feedback effect on central gonadotropin release and subsequent ovarian production of estrogen; however, it is sometimes necessary to use continuous estrogen to control the symptoms. This use of estrogen can often lead to undesirable side effects and even the risk of endometrial cancer.

35 Another treatment consists of continuous administration of progestins which induces amenorrhea and by suppressing ovarian estrogen production can cause regressions of the endometrial growths. The use of chronic progestin therapy is often accompanied by the unpleasant CNS side effects of progestins and often leads to infertility due to suppression of ovarian function.

40 A third treatment consists of the administration of weak androgens, which are effective in controlling the endometriosis, however, they induce severe masculinizing effects. Several of these treatments for endometriosis have also been implicated in causing a mild degree of bone loss with continued therapy. Therefore, new methods of treating endometriosis are desirable.

45 Smooth aortal muscle cell proliferation plays an important role in diseases such as atherosclerosis and restenosis. Vascular restenosis after percutaneous transluminal coronary angioplasty (PTCA) has been shown to be a tissue response characterized by an early and late phase. The early phase occurring hours to days after PTCA is due to thrombosis with some vasospasms while the late phase appears to be dominated by excessive proliferation and migration of aortal smooth muscle cells. In this disease, the increased cell motility and colonization by such muscle cells and macrophages contribute significantly to the pathogenesis of the disease. The excessive proliferation and migration of vascular aortal smooth muscle cells may be the primary mechanism to the reocclusion of coronary arteries following PTCA, atherectomy, laser angioplasty and arterial bypass graft surgery. See "Intimal Proliferation of Smooth Muscle Cells as an Explanation for Recurrent Coronary Artery Stenosis after Percutaneous Transluminal Coronary Angioplasty," Austin et al., Journal of the American College of Cardiology, 8: 369-375 (Aug 1985)

50 Vascular restenosis remains a major long term complication following surgical intervention of blocked arteries by percutaneous transluminal coronary angioplasty (PTCA), atherectomy, laser angioplasty and arterial bypass graft surgery. In about 35% of the patients who undergo PTCA, reocclusion occurs within three to six months after the procedure. The current strategies for treating vascular restenosis include mechanical intervention by devices such as stents or pharmacologic therapies including heparin, low molecular weight heparin, coumarin, aspirin, fish oil, calcium antagonist, steroids, and prostacyclin. These strategies have failed to curb the reocclusion rate and have been ineffective for the treatment and prevention of vascular restenosis. See "Prevention of Restenosis after Percutaneous Transluminal

Coronary Angioplasty The Search for a 'Magic Bullet,' Hermans *et al.*, American Heart Journal, 122: 171-187 (July 1991)


In the pathogenesis of restenosis excessive cell proliferation and migration occurs as a result of growth factors produced by cellular constituents in the blood and the damaged arterial vessel wall which mediate the proliferation of smooth muscle cells in vascular restenosis

Agents that inhibit the proliferation and/or migration of smooth aortal muscle cells are useful in the treatment and prevention of restenosis. The present invention provides for the use of compounds as smooth aortal muscle cell proliferation inhibitors and, thus inhibitors of restenosis

Transforming growth factor- β (TGF- β) is a peptide growth factor which refers to a generic family of peptides, often called isoforms meaning that members of the family either share amino acid homology and/or have similar physiological actions. The TGF- β 's, particularly those designated TGF- β_1 , β_2 , and β_3 , are particularly associated with processes involved in tissue repair and diseases associated with abnormal repair processes (see, Sporn and Roberts "The Transforming Growth Factor- β 's", Peptide Growth Factors and their Receptors I, 419-472 (Berlin: Springer Verlag, 1990)).

Agents which induce the production of TGF- β 's, and in particular TGF- β_3 , are useful in promoting tissue repair and treating diseases which involve abnormal tissue repair. Such utilities include but are not limited to wound-healing, reduction of scarring (see, Ferguson, "Wound Healing, Scarring, TGF- β Antagonists, and Isoforms", Abst NIH TGF- β Symposium, Bethesda MD, 3 May 1994), and ulcerative mucositis induced by chemotherapy and radiotherapy (see, Sonis and Haley, "Prevention of Chemotherapy-Induced Ulcerative Mucositis by Transforming Growth Factor- β_3 ", Abst. NIH TGF- β Symposium, Bethesda MD, 3 May 1994). The present invention provides for the use of compounds as promoters of tissue repair processes and as treatments for diseases involving abnormal tissue repair

The present invention relates to compounds of formula I



wherein

X is -O-, -S-, or -NR⁵-;

Y is -O-, -S-, -CH₂-, -CH₂CH₂-, -CH=CH-, or -NR⁵-;

R¹, R², and R³ are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₄-C₆ alkyl), -OSO₂CF₃, Cl, or F,

n is 1 or 2,


W is CH₂ or C=O,

R⁴ is 1-piperidinyl, 2-oxo-1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino.

R⁵ is C₁-C₃ alkyl, -COC₆H₅, -CO(C₁-C₆ alkyl), -C(O)OC₆H₅, -C(O)O(C₁-C₆ alkyl), -SO₂(C₁-C₆ alkyl), -SO₂C₆H₅, or -SO₂CF₃;

or a pharmaceutically acceptable salt thereof

Also provided by the present invention are compounds of formula II




wherein

B is -CH₂- or -CO-

Y, R¹, R², R³, R⁴, n, and W are as defined above, or a pharmaceutically acceptable salt thereof

25 Also provided by the present invention are intermediate compounds of formula III and VI which are useful for preparing the pharmaceutically active compounds of the present invention, and are shown below



45 wherein

R^{1a}, R^{2a}, and R^{3a} are each independently -H, -O(C₁-C₄ alkyl), -Cl, -F, or a suitably protected hydroxyl,

Z is -OH, -OC₆H₅, -O(C₁-C₄ alkyl), or 4-hydroxyphenyl,

X and Y are as defined above,


5

10

15

20

wherein

 R^{1a} , R^{2a} , R^{3a} , and Y are as defined above

The present invention further relates to pharmaceutical compositions containing compounds of formula I or formula II, optionally containing estrogen or progestin, and the use of such compounds, alone, or in combination with estrogen or progestin, for alleviating the symptoms of post-menopausal syndrome, particularly osteoporosis, cardiovascular related pathological conditions, and estrogen-dependent cancer. As used herein, the term "estrogen" includes steroid compounds having estrogenic activity such as, for example, 17 β -estradiol, estrone, conjugated estrogen (Premarin®), equine estrogen, 17 α -ethynodiol and the like. As used herein, the term "progestin" includes compounds having progestational activity such as, for example, progesterone, norethynodrel, norgestrel, megestrol acetate, norethindrone, and the like.

The compounds of the present invention also are useful for inhibiting uterine fibroid disease and endometriosis in women and aortal smooth muscle cell proliferation, particularly restenosis, in humans.

Also provided by the present invention is a process for preparing a compound of formula Ia

35


40

45

50

55

wherein



X and Y are as defined above,


G is -OH or $-\text{O}(\text{CH}_2)_n\text{WR}^4$

wherein

n, W and R^4 are as defined above, or a pharmaceutically acceptable salt thereof, which comprises

a) reacting a compound of formula IIIa

10



15

20

wherein

R^{1a} , R^{2a} , R^{3a} , X, and Y are as defined above,

Z^a is -OH, $-\text{OC}_6\text{H}_5$, $-\text{O}(\text{C}_1\text{-}\text{C}_4\text{ alkyl})$, with a Grignard reagent of formula IVa

30



35

wherein

G^a is $-\text{OSi}(\text{CH}_3)_3$, a suitably protected hydroxyl which can be selectively deprotected in the presence of R^{1a} , R^{2a} , and R^{3a} , or $-\text{O}(\text{CH}_2)_n\text{WR}^4$

wherein

n, W, and R^4 are as defined above


45

- b) when G^a is $-\text{OSi}(\text{CH}_3)_3$ or another suitable protecting group optionally removing the said protecting group and thereafter reacting the resulting -OH with $\text{Q}-(\text{CH}_2)_n\text{W-R}^4$ wherein Q is bromo, chloro, or hydroxy, and
- c) optionally silylating the reaction product from step a) or b).

One aspect of the present invention includes compounds of formula I

50

55



wherein

X is -O-, -S-, or -NR⁵-;

Y is -O-, -S-, -CH₂-, -CH₂CH₂-, -CH=CH-, or -NR⁵-;

25 R¹, R², and R³ are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₄-C₆ alkyl), -OSO₂CF₃, Cl, or F,

n is 1 or 2,

W is CH₂ or C=O;

30 R⁴ is 1-piperidinyl, 2-oxo-1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino;

R⁵ is C₁-C₃ alkyl, -COC₆H₅, -CO(C₁-C₆ alkyl), -C(O)OC₆H₅, -C(O)O(C₁-C₆ alkyl), -SO₂(C₁-C₆ alkyl), -SO₂C₆H₅, or -SO₂CF₃:

or a pharmaceutically acceptable salt thereof.

35 General terms used in the description of compounds herein described bear their usual meanings. For example, "C₁-C₆ alkyl" refers to straight or branched aliphatic chains of 1 to 6 carbon atoms including methyl, ethyl, propyl, isopropyl, butyl, n-butyl, pentyl, isopentyl, hexyl, isohexyl, and the like


The starting material for one route of preparing compounds of the present invention are compounds of formula V below.

40

45

50

55




wherein

R^{1a}, R^{2a} and R^{3a} are each independently -H, -O(C₁-C₄ alkyl), -F, -Cl, or a suitably protected hydroxyl. X and Y are as defined above.

One embodiment of this starting material, compounds of formula Vb

5

10



15

20

Vb

wherein

25

R^{1a}, R^{2a}, and R^{3a} are as defined above;


X' is -O-, -S-, or -NH-,

are made essentially as described in Journal of Organic Chemistry, 40 3169 (1975). Preferably, R^{1a} and R^{2a} are methoxy or a suitably protected hydroxyl, R^{3a} is -H, and X' is -O-

30

In general, a readily available thioindoxyl of the formula

35




40

wherein R^{2a} is as defined above, is reacted with a benzaldehyde of the formula

45

50



55

wherein X^b is -OH, -SH, or -NH₂, and R^{1a} and R^{2a} are as defined above. The reaction generally is carried out in the presence of a mild base such as triethylamine and a protic solvent such as ethanol, and is run at ambient temperature or below. The product of this condensation is then dehydrogenated by various methods known in the art, most preferably via reaction with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to give a compound of formula V.


If so desired, a compound of formula V in which R^{1b}, R^{2b}, and/or R^{3b} is methoxy may be deprotected by reaction with aluminum trichloride and ethanethiol and reprotected with an alternative phenol protecting group at this stage. Protecting groups which are removable under mild conditions such as t-butyldimethylsilyl are preferred.

Alternative starting materials of formula Vc

5

10

15



20

wherein

R^{1c} and R^{2c} are suitably protected hydroxyls; are available by standard protection of commercially available coumestrol. Protecting groups which are removable under mild conditions such as t-butylidemethylsilyl are preferred.

Starting materials of formula Vd


25

30

35

40

wherein




50

In general, a readily available tetralone or indanone of the formula

55

5




10

wherein R^{2a} is as defined above, and y^d is -CH₂- or -CH₂-CH₂-, is condensed with an appropriately substituted phenol or thiophenol

15

20



30

R^{1a'} is -OH, -H, -O(C₁-C₄ alkyl), -F, -Cl, or a suitably protected hydroxyl; R^{3a} is as defined above, and X^d is -OH or -SH, under the influence of a condensing agent such as phosphorus oxychloride, phosphorus pentoxide, sulfuric acid, aluminum chloride or the like. Preferably R^{1a'} is -OH, R^{3a} is -H, X^d is OH, Y^d is CH₂CH₂, and R^{2a} is methoxy and the reaction is carried out in toluene or benzene at 80-110°C utilizing phosphorus oxychloride as the condensing agent.

35


If the von Pechman product contains a phenolic moiety it may be protected at this stage, or alternatively if R^{2d} is methoxy, it may be subjected to a dealkylation/reprotection sequence as described supra. If so desired, the optional double bond may then be installed by reaction with DDQ or another dehydrogenating agent

Additional starting materials of formula Ve

40

45

50



55

X^e and Y^e are each independently -O-, -S-, -NH-, or -NR⁵;

R^{1a}, R^{2a}, R^{3a}, and R⁵ are as defined above, are prepared essentially as described in Heterocycles, 35:1425 (1993), United States patent number 5,073,553 issued December 17, 1991; and Indian Journal of Chemistry, 24B: 556

(1989)


Other starting materials, of the formula

5

10

A.

15



20

wherein

R^{1a}, R^{2a}, and R^{3a} are as defined above,X^f is -NH- or -NR⁵-; and

25

Y^f is -CH₂- or -CH₂-CH₂- or -CH=CH-, are prepared essentially as described in Indian Journal of Chemistry, 14B 132 (1976) and in Journal of the Chemical Society, Perkin Trans. I, 1747 (1974). If the double bond (Y^f= -CH=CH-) is desired, it may be obtained in the manner described supra, by the use of DDQ.


30

Once a compound of formula V_f has been formed, one option allows for reduction of the selected formula V compound to a compound of formula IIIb

35

40

45



wherein

50


R^{1a}, R^{2a}, R^{3a}, X, and Y are as defined above, by reaction with an appropriate reducing agent such as diisobutylaluminum hydride in a solvent such as toluene, CH₂Cl₂, or THF. Generally this reduction is carried out at a temperature below 0°C and preferably between -50°C and -100°C. The formula IIIb compound may then be converted, either *in situ* or in a separate step to a compound of formula IIIc below

55

5

10

15



IIIc

wherein

20 R⁶ is -C₁-C₄ alkyl or -C₆H₅ or
 R^{1a}, R^{2a}, R^{3a}, X, and Y are as defined above,
 by reaction with an alcohol or phenol R⁶OH and, optionally an acidic compound or dehydrating agent such as
 magnesium sulfate. It is preferable to carry out this conversion in a separate step, in CH₂Cl₂ or chlorobenzene,
 between ambient temperature and reflux. Preferably, R^{1a} and R^{2a} are suitably protected hydroxyls, R^{3a} is H X is
 25 -O-, Y is -O- or -S-, and R⁶ is -C₆H₅.

30 Alternatively, a compound of formula V in which X is -NH- may be acylated on nitrogen and then directly converted
 to a formula IIIc compound by reaction with NaBH₄ or a similar reducing agent in the presence of an acidic compound
 such as HCl and an alcoholic solvent. In this embodiment of IIIc it is preferable that R^{1a} and R^{2a} are methoxy, R^{3a} is
 H, X is -N(COC₆H₅)- or -N(COC(CH₃)₄)-, Y is -O-, and R⁶ is preferably -C₂H₅.

In the next step, a formula IIb or IIIc compound is reacted with an aryl Grignard reagent of formula

35

40




IVa

wherein

45 G^a is -OSi(CH₃)₃, a suitably protected hydroxyl which can be selectively deprotected in the presence of R^{1a} and
 R^{2a} or -(CH₂)_nWR⁴,
 wherein
 n, W, and R⁴ are as defined above,
 in a solvent such as toluene, THF, diethyl ether, CH₂Cl₂, or a mixture thereof and at ambient temperature or below
 50 Optionally, the reaction may be facilitated by the presence of a Lewis acid such as boron trifluoride etherate, tin
 tetrachloride, titanium tetrachloride or the like

When G^a of formula IVa is -O(CH₂)_nWR⁴ this Grignard reaction provides a compound of formula Ib


55



wherein


R^{1a}, R^{2a}, and R^{3a} are each independently -H, -O(C₁-C₄ alkyl), -Cl, -F, or a suitably protected hydroxyl;
X, Y, n, W, and R⁴ are as defined above;

which can be optionally deprotected and derivatized as described infra to provide the desired formula I compound.
Alternatively, when G^a of formula IVa is -OSi(CH₃)₃ or another suitably protected hydroxyl, the protecting group is cleaved at this stage under conditions which leave R^{1a}, R^{2a}, and R^{3a} intact, to provide a compound of formula Ic




50 wherein
R^{1a}, R^{2a}, R^{3a}, X, and Y are as defined above. Such conditions are dependent upon the nature of the protecting groups and are known to those skilled in the art [see, e.g., Greene and Wuts, Protective Groups in Organic Synthesis, 2nd ed., (1991)]. In a preferred embodiment, in which R^{1a} and R^{2a} are t-butyldimethylsilyloxy or methoxy, R^{3a} is H, and G^a is -OSi(CH₃)₄ this may be accomplished by brief exposure to a methanolic slurry of potassium carbonate at ambient temperature or below in the presence of a cosolvent such as THF or diethyl ether

55 A formula Ic compound may be converted to a formula Ib compound by utilizing one of the synthetic routes shown in Scheme I. In Scheme I, R^{1a}, R^{2a}, R^{3a}, R⁴, W, X, Y, and n are as defined above


Scheme I

Each step of Scheme I is carried out via procedures well known to one of ordinary skill in the art
 For example, a formula Ic compound can be reacted with a compound of the formula



wherein R⁴, W, and n are as defined above and Q is a bromo or, preferably, a chloro moiety, to provide compounds of formula Ib. This alkylation is normally achieved by carrying out the reaction in the presence of an excess of finely powdered potassium carbonate and using an equivalent to slight excess of the Q-(CH₂)_n-R³ reactant.

A more preferred method involves the reaction of a formula Ic compound with a compound of formula



wherein R⁴, W, and n are as defined above in the presence of triphenylphosphine, diethyl azodicarboxylate (DEAD), and an appropriate solvent, resulting in a formula Ib compound. This process is known in the art as a Mitsunobu coupling. Preferably, 2-4 equivalents of 1-(2-hydroxyethyl)pyrrolidine are reacted with a formula Ic compound in the presence of 2-5 equivalents each of triphenylphosphine and DEAD, in an inert solvent such as toluene at ambient temperature. At this temperature the reaction only takes about 30 minutes to about 3 hours, however changes in the reaction conditions will influence the amount of time this reaction needs to be run to completion. Of course, the progress of this reaction step can be monitored via standard chromatographic techniques.

In yet another synthetic route, a formula Ic compound is reacted with an excess of an alkylating agent of the formula



wherein J and J' each are the same or different leaving group, in an alkali solution


Appropriate leaving groups include, for example, the sulfonates such as methanesulfonate, 4-bromosulfonate,

toluenesulfonate, ethanesulfonate, isopropanesulfonate, 4-methoxybenzenesulfonate, 4-nitrobenzenesulfonate, 2-chlorobenzene sulfonate, and the like, halogens such as bromo, chloro, iodo, and the like, and other related groups. A preferred alkylating agent is 1,2-dibromoethane, and at least 2 equivalents, preferably, more than 2 equivalents, of 1,2-dibromoethane is used per equivalent of substrate.

5 A preferred alkali solution for this alkylation reaction contains potassium carbonate in an inert solvent such as, for example, methylethyl ketone (MEK) or DMF. In this solution the 4-hydroxy group of the benzoyl moiety of a formula IIId compound exists as a phenoxide ion which displaces one of the leaving groups of the alkylating agent.

This reaction is best run when the alkali solution containing the reactants and reagents is brought to reflux and allowed to run to completion. When using MEK as the preferred solvent, reaction times run from about 6 hours to about 10 20 hours.

Alternatively, a compound of formula Id can be prepared by the reaction of an alcohol of formula



15 wherein J is selected from the leaving groups described above, with a formula Ic compound via a Mitsunobu coupling procedure. A preferred alcohol is 2-bromoethanol.

The reaction product from this step, a compound of formula Id, is then reacted with 1-piperidine, 1-pyrrolidine, methyl-1-pyrrolidine, dimethyl-1-pyrrolidine, 4-morpholine, dimethylamine, diethylamine, or 1-hexamethyleneimine, via 20 standard techniques, to form compounds of formula Ib. Preferably, the hydrochloride salt of piperidine is reacted with the formula Ib compound in an inert solvent, such as anhydrous DMF, and heated to a temperature in the range from about 60° C to about 110° C. When the mixture is heated to a preferred temperature of about 90° C, the reaction only takes about 30 minutes to about 1 hour. However, changes in the reaction conditions will influence the amount of time 25 this reaction needs to be run to completion. Of course, the progress of this reaction step can be monitored via standard chromatographic techniques.

Dealkylation/deprotection of terminally-protected hydroxy groups in formula Ia compounds can be carried out if so desired to provide pharmaceutically active compounds of formula I. via procedures known to one of ordinary skill in the art. A preferred method for the deprotection of t-butylidimethylsilyl ethers, a preferred embodiment of R^{1a} and R^{2a}, involves stirring them in an appropriate solvent such as THF with a soluble fluoride source such as tetra-n-butylammonium fluoride at ambient temperature.


30 The above procedures provide novel, pharmaceutically active compounds of formula I in which R¹, R², and R³ each are hydrogen, hydroxy, C₁-C₄ alkoxy, chloro, or fluoro. Preferred formula Ia compounds are those in which R¹ and R² each are methoxy, or R¹ and R² each are hydroxy, R³ is H, R⁴ is piperidinyl or pyrrolidinyl, X is -O-, Y is -S-, W is -CH₂-_n, and n is 1. These preferred compounds, as well as other formula Ia compounds, can be used as pharmaceutical agents or can be further derivitized to provide other formula I compounds which also are useful for practicing 35 the methods of the present invention.

An alternative "one-pot" method for the preparation of a formula I or Ia compound from a compound of formula V can also be employed. This route involves:

- 40 1) The reduction of a formula V compound by diisobutylaluminum hydride or a similar reducing agent in THF at a temperature below -60° C
 2) Quenching of excess reducing agent with a molar equivalent of a protic solvent such as methanol or isopropanol
 3) Addition of an aryl Grignard reagent of the formula

45

50



and warming to ambient temperature

- 55 4) Standard extractive work-up of the reaction mixture and concentration.
 5) Optional treatment of a THF solution of the remnant with a strong acid, such as HCl, for a period of up to 24 h and subsequent basic work-up

In some cases, the "one-pot" method may provide formula Ia products which may be deprotected as described

⁵ supra. Alternatively, the final acid treatment may induce concomitant deprotection and result in the direct preparation of formula I compounds. Preferred formula I compounds from this reaction are the same as those preferred formula I compounds described above, and can be used as pharmaceutically active agents for the methods herein described, or can be derivatized to provide other novel compounds of formula I which also are useful for the present methods (infra)


Another aspect of the present invention includes compounds of formula II

10

15

20

25



³⁰ wherein

B is -CH₂- or -CO-

Y, R¹, R², R³, R⁴, n, and W are as defined above, or a pharmaceutically acceptable salt thereof

³⁵ A key intermediate in the preparation of formula II compounds is a compound of formula VI


35

40

45

50

55




VI

55


wherein

R^{1a}, R^{2a}, R^{3a}, and Y are as defined above. The synthesis of a preferred embodiment of VI, VIa in which Y is -CH₂CH₂- is described in Scheme II

Scheme II

40 Thus, a readily available tetralone VIIa wherein R^{2a} is as defined above is condensed with one equivalent of 4-aminophenol, preferably in the absence of solvent, at a temperature such that the mixture is molten, usually c. 180°C under a nitrogen stream. During the course of the reaction, additional 4-aminophenol may be added to replace material lost via sublimation. The resulting imine of formula VIIIia solidifies upon cooling, and may be optionally recrystallized.

45 Protection of the hydroxyl group of VIIIia as its silyl derivative VIIIia' is carried out under standard conditions, and the imine is converted to an enamide of formula IXa by acylation with an aryl halide of formula




wherein R^{1a} and R^{2a} are as defined above, generally in the presence of a mild base such as triethylamine and in an inert solvent such as CH₂Cl₂ at a temperature between ambient and reflux

A compound of formula IXa is then photolyzed in a quartz immersion well, using a Hanovia mercury lamp in a solvent such as ether or benzene, for a period of 4h to 1 week to provide a compound of formula VIa'. The procedure is essentially as described in Journal of the Chemical Society, Perkin Transactions I, 762 (1975)

Desilylation of a formula VIa' compound under standard conditions then provides a compound of formula VIa. For a listing of appropriate conditions see, e.g., Greene and Wuts, Protective Groups in Organic Synthesis, 2nd ed., p 80, 161 (1991). Preferred formula VI compounds are those in which R^{1a} and R^{2a} are each individually -H or methoxy, and R^{3a} is -H. Most preferred is the compound in which both R^{1a} and R^{2a} are methoxy.


A compound of formula VI is converted to a compound of formula IIb



wherein

R^{1a}, R^{2a}, R^{3a}, R⁴, Y, n, and W are as described above, by the methods described supra for the conversion of formula Ic compounds to formula Ib compounds. For example, a preferred method is the Mitsunobu coupling of a formula VI compound with 1-(2-hydroxyethyl)pyrrolidine or 1-(2-hydroxyethyl)piperidine.

Once a formula IIb compound is obtained, it may be optionally deprotected/dealkylated to provide a formula II compound or, alternatively it may be reduced to provide a compound of formula IIc




wherein

R^{1a}, R^{2a}, R^{3a}, R⁴, Y, n, and W are as described above. One method for carrying out this reduction involves reacting a formula IIa compound with lithium aluminum hydride in an inert solvent such as THF. If the reaction is carried out at ambient temperature an intermediate product can be isolated which, upon further reduction with sodium borohydride in acetic acid is converted to a formula IIc compound. Alternatively, if the reaction is carried out at reflux the desired formula IIc compound can be isolated directly. Compounds of formula IIc can be optionally dealkylated/deprotected to provide compounds of formula II.

In the preferred case where Y is -CH₂CH₂-, i.e. formula IIa

10



25

wherein

R^{1a}, R^{2a}, R^{3a}, R⁴, n, and W are as described above; it may be desirable to carry out a dehydrogenation reaction, thus providing a compound of formula IIId

35

40

45


IIId

50

wherein


R^{1a}, R^{2a}, R^{3a}, R⁴, n, and W are as described above. This dehydrogenation may be effected by various methods known in the art, most preferably via reaction with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ).

Alternatively, it may be desirable to perform the dehydrogenation at an earlier stage in the synthesis on a compound of formula VIa' to provide a compound of formula VIb:



15 Compounds of formula VIb may then be converted to compounds of formula IIe by methods analogous to the conversion of VIa to IIa.

The formula IIc compound can be optionally deprotected/dealkylated to provide a compound of formula II, or alternatively can be reduced, as described supra to provide a compound of formula IIe



wherein

40 R^{1a}, R^{2a}, R^{3a}, R⁴, n, and W are as described above. A compound of formula IIe may then be optionally deprotected/dealkylated to provide a compound of formula II.

Collectively, formula IIa-e compounds with their various defined substituents, and/or the products of their deprotection as described above, are represented as compounds of formula II of the present invention.

45 For example when R^{1a}, R^{2a}, and/or R^{3a} of a formula IIe compound are C₁-C₄ alkyl hydroxy protecting groups, such groups can be removed via standard dealkylation techniques to prepare an especially preferred compound of formula IIe. In the most preferred examples of formula II compounds R¹ and R² are each individually -H, -OH, or methoxy, Y is -CH=CH-, B is -CH₂-, n is 1, W is -CH₂-, and R⁴ is 1-piperidinyl or 1-pyrrolidinyl

50 An alternative method involves the formation of preferred compounds of formula I or II by replacing the R¹, R², and/or R³ hydroxy groups of a formula I or formula II compound with methoxy. This transformation is carried out by well known procedures (see, e.g., Greene and Wuts, Protective Groups in Organic Synthesis, 2nd ed., p. (1991)). An especially preferred method involves reaction of the mono- or diphenolic compound with excess diazomethane.

55 Other preferred compounds of formula I or II are prepared by replacing the newly formed R¹, R² and/or R³ hydroxy groups of a formula I or formula II compound with a moiety of the formula -O-CO-(C₁-C₆ alkyl), or -O-SO₂-(C₄-C₆ alkyl) via well known procedures. See, e.g., U.S. Pat. No. 4,358,593

For example, when an -O-CO(C₁-C₆ alkyl) group is desired, the dihydroxy compound of formula I is reacted with an agent such as acyl chloride, bromide, cyanide, or azide, or with an appropriate anhydride or mixed anhydride. The reactions are conveniently carried out in a basic solvent such as pyridine, lutidine, quinoline or isoquinoline, or in a tertiary amine solvent such as triethylamine, tributylamine, methylpiperidine, and the like. The reaction also may be carried out in an inert solvent such as ethyl acetate, dimethylformamide, dimethylsulfoxide, dioxane, dimethoxyethane,

acetonitrile, acetone, methyl ethyl ketone, and the like, to which at least one equivalent of an acid scavenger (except as noted below), such as a tertiary amine, has been added. If desired, acylation catalysts such as 4-dimethylaminopyridine or 4-pyrrolidinopyridine may be used. See, e.g., Haslam, et al., *Tetrahedron*, 36, 2409-2433 (1980).

The acylation reactions which provide the aforementioned terminal R¹, R² and R³ groups of compounds of formula I or formula II are carried out at moderate temperatures in the range from about -25° C to about 100° C, frequently under an inert atmosphere such as nitrogen gas. However, ambient temperature is usually adequate for the reaction to run.

Such acylations of these hydroxy group also may be performed by acid-catalyzed reactions of the appropriate carboxylic acids in inert organic solvents or heat. Acid catalysts such as sulfuric acid, polyphosphoric acid, methanesulfonic acid, and the like are used.

The aforementioned R¹, R² and/or R³ groups of formula I or formula II compounds also may be provided by forming an active ester of the appropriate acid such as the esters formed by such known reagents such as dicyclohexylcarbodiimide, acylimidazoles, nitrophenols, pentachlorophenol, N-hydroxysuccinimide, and 1-hydroxybenzotriazole. See, e.g., *Bull. Chem. Soc. Japan*, 38:1979 (1965), and *Chem. Ber.*, 788 and 2024 (1970).

Each of the above techniques which provide -O-CO-(C₁-C₆ alkyl) moieties are carried out in solvents as discussed above. Those techniques which do not produce an acid product in the course of the reaction, of course, do not call for the use of an acid scavenger in the reaction mixture.

When a formula I or formula II compound is desired in which the R¹, R² and/or R³ group of a formula I compound is converted to a group of the formula -O-SO₂-(C₄-C₆ alkyl) or -O-SO₂-CF₃, the formula I dihydroxy compound is reacted with, for example, a sulfonic anhydride or a derivative of the appropriate sulfonic acid such as a sulfonyl chloride, bromide, or sulfonyl ammonium salt, as taught by King and Monoir, *J. Am. Chem. Soc.*, 97, 2566-2567 (1975), or with a reagent such as N-phenyltrifluoromethanesulfonimide, as taught by Hendrickson and Bergeron, *Tetrahedron Letters*, 4607 (1973). The dihydroxy compound also can be reacted with the appropriate sulfonic anhydride, mixed sulfonic anhydrides, or sulfonimides. Such reactions are carried out under conditions such as were explained above in the discussion of reaction with acid halides and the like.

In the case where R¹, R² and/or R³ of a formula I or formula II compound has been converted to -O-SO₂-CF₃, said derivative can be further converted to a compound of formula I or formula II in which -O-SO₂-CF₃ groups have been replaced by -H. Thus the formula I or formula II trifluoromethanesulfonate is reduced under conditions described in Example 7, *infra*, or as taught by Ritter, *Synthesis*, 735 (1993).

Although the free-base forms of formula I and formula II compounds can be used in the methods of the present invention, it is occasionally advantageous to prepare and use a pharmaceutically acceptable salt form. Thus, the compounds used in the methods of this invention primarily form pharmaceutically acceptable acid addition salts with a wide variety of organic and inorganic acids, and include the physiologically acceptable salts which are often used in pharmaceutical chemistry. Such salts are also part of this invention. Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric, and the like. Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alcanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used. Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, b-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, caprate, caprylate, chloride, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, terephthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzenesulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like. A preferred salt is the hydrochloride salt.

The pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of formula I or formula II with an equimolar or excess amount of acid. The reactants are generally combined in a mutual solvent such as diethyl ether or ethyl acetate. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.


The pharmaceutically acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.

The following examples are presented to further illustrate the preparation of compounds of the present invention. It is not intended that the invention be limited in scope by reason of any of the following examples.

NMR data for the following Examples were generated on a GE 300 MHz NMR instrument, and anhydrous acetone-*d*₆ was used as the solvent unless otherwise indicated.

Preparation 1a**6-Methoxythianaphthen-2-one**

5



10

To tetrahydrofuran (200 mL) containing 2-dimethylamino-6-methoxybenzo-[*b*]-thiophene (cf. U.S. 5,420,349) (20.00 g, 96.5 mmol) was added 1N aqueous HCl (200 mL) and the resulting mixture was heated to reflux for 3 h. The mixture was cooled, the layers were separated, and the aqueous layer was extracted with dichloromethane (300 mL). The combined organic layers washed with water (250 mL), dried (MgSO_4), filtered and concentrated to give crude product, which was recrystallized from 3A-ethanol, and dried *in vacuo* at room temperature to afford the title compound (13.89 g, 77.0 mmol, 80%); mp 80–82 °C; IR (KBr) 1713, 1605, 1485, 1287, 1015, 865, 813 cm^{-1} ; ^1H NMR (DMSO-d_6) δ 7.22 (d, 1 H, J = 8.4 Hz), 7.11 (s, 1 H), 6.78 (d, 1 H, J = 8.4 Hz), 4.06 (s, 2 H), 3.71 (s, 3 H); ^{13}C NMR (DMSO-d_6) δ 203.5, 159.0, 136.9, 125.6, 124.6, 112.3, 108.4, 55.3, 46.2. Anal. Calcd. for $\text{C}_9\text{H}_8\text{O}_2\text{S}$: C, 59.98; H, 4.47; S, 17.78. Found: C, 60.19, H, 4.57, S, 18.03.


15

Preparation 1b**6a,11a-Dihydro-3,9-dimethoxy-6-*H*[1]benzothieno[3,2-*c*] [1]benzopyran-6-one**

20

25

30



35

To a stirred solution of 6-methoxythianaphthen-2-one (see Docket B-9459) (20 g, 111 mmol) in a mixture of ethanol (100 mL) and methylene chloride (50 mL) was added 4-methoxysalicylaldehyde (17.5 g, 115 mmol) followed by triethylamine (567 mg, 784 mL, 5.6 mmol) at room temperature. After 30 min, a solid began to precipitate and stirring was continued overnight. The mixture was then diluted with cold hexane (1 L) and filtered to yield 28.7 g (82%) of the title product as an off-white solid, pure by $^1\text{H-NMR}$ analysis. An analytical sample was obtained by recrystallization from toluene as light yellow crystals, mp 157–165 °C; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ 7.33 (d, J = 8.6 Hz, 1 H), 7.31 (d, J = 8.1 Hz, 1 H), 6.75 (d, J = 2.4 Hz, 1 H), 6.70 (m, 2 H), 6.60 (d, J = 2.5 Hz, 1 H), 5.22 (d, J = 7.2 Hz, 1 H), 4.33 (d, J = 7.2 Hz, 1 H), 3.79 (s, 3 H), 3.76 (s, 3 H); IR (CHCl_3) 1759 cm^{-1} ; MS (FD) m/e 314 (M $^+$); Anal. calc'd for $\text{C}_{17}\text{H}_{14}\text{O}_4\text{S}$: C, 64.95; H, 4.50. Found: C, 65.01, H, 4.58.


40

45

Preparation 2**3,9-Dimethoxy-6-*H*[1]benzothieno[3,2-*c*] [1]benzopyran-6-one**

50

55



A mixture of the product of Preparation 2 (4.5 g, 14.3 mmol) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (3.4 g, 15 mmol) in dichloroethane (100 mL) was heated briefly to 80°C, inducing the formation of a precipitate. The mixture was filtered hot, rinsing the precipitate with methylene chloride, and the mother liquor concentrated *in vacuo*. The remnant was dissolved in hot methylene chloride, filtered to remove residual hydroquinone, and reconcentrated.

5 The product was recrystallized from toluene to provide 3.94 g (88%) of the title product as white needles, mp 220–221°C. ¹H-NMR (acetone-*d*₆/DMSO-*d*₆) δ 8.41 (d, J = 8.9 Hz, 1H), 7.82 (d, J = 8.7 Hz, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.20 (dd, J = 8.9, 2.4 Hz, 1H), 7.09 (d, J = 2.4 Hz, 1H), 7.03 (dd, J = 8.6, 2.4 Hz, 1H), 3.94 (s, 3H), 3.91 (s, 3H); IR (KBr) 1717 cm⁻¹; MS (FD+) m/e 312 (M⁺); Anal. calc'd. for C₁₇H₁₂O₄S: C, 65.37; H, 3.88. Found: C, 65.51; H, 3.90.


10 **Preparation 3**

3,9-Bis[(*tert*-butyldimethylsilyl)oxy]-6-*H*-[1]benzothieno[3,2-*c*] [1]benzopyran-6-one

15

20

25



To a mechanically stirred slurry of the product of Preparation 2 (12 g, 38.4 mmol) in methylene chloride (220 mL) was added ethanethiol (11.9 g, 13.4 mL, 192 mmol) followed by aluminum chloride (38.4 g, 288 mmol), portionwise. The reaction mixture was stirred at ambient temperature for 5 h, then cooled to 0°C and quenched cautiously with tetrahydrofuran (THF) (250 mL) followed by saturated sodium bicarbonate (250 mL). The mixture was diluted with THF (1 L), the layers separated, and the aqueous layer was washed with THF (200 mL). The combined organic layers were dried (sodium sulfate) and concentrated to yield 11.1 g (102%) of crude diphenol as a yellow solid, which was used without further purification.

The crude product was slurried in methylene chloride (220 mL) and treated with triethylamine (20.2 g, 28 mL, 200 mmol) and *tert*-butyldimethylsilyl chloride (20.3 g, 134.4 mmol). The mixture was stirred at ambient temperature for 5 h, during which it slowly became homogeneous. After dilution with hexane (600 mL), the mixture was washed with brine (600 mL) and the aqueous layer was extracted with hexane (300 mL). The combined organic layers were dried (sodium sulfate), concentrated, and the residue recrystallized from hexane to provide 18.0 g (91%) of the title compound as a fluffy white solid, mp 142–144°C. ¹H-NMR (300 MHz, CDCl₃) δ 8.50 (d, J = 8.7 Hz, 1H), 7.58 (d, J = 8.5 Hz, 1H), 7.32 (d, J = 2.1 Hz, 1H), 7.05 (dd, J = 6.7, 2.1 Hz, 1H), 6.92 (d, J = 2.2 Hz, 1H), 6.84 (dd, J = 8.4, 2.2 Hz, 1H), 1.01 (s, 9H), 1.00 (s, 9H), 0.27 (s, 6H), 0.25 (s, 6H); ¹³C-NMR (75 MHz, DMSO-*d*₆) δ 158.4, 157.0, 154.6, 152.7, 149.6, 138.5, 130.5, 125.2, 124.6, 120.0, 117.6, 116.3, 112.7, 111.3, 108.0, 25.6, 25.6, 18.2, 18.2, -4.4, -4.4; IR (CHCl₃) 1717 cm⁻¹; MS (FD) m/e 512 (M⁺); Anal. calc'd. for C₂₇H₃₆O₄SSi₂: C, 63.24; H, 7.08. Found: C, 63.45; H, 7.36.


45

50

55

Preparation 43,9-Bis[(*tert*-butyldimethylsilyl)oxy]-6-*H*[1]benzothieno[3,2-*c*] [1]benzopyran-6-ol


5



15

A solution of the product from Preparation 3 (2.0 g, 3.9 mmol) in toluene (200 mL) was cooled to -92°C and treated dropwise with a 1.0 M toluene solution of diisobutylaluminum hydride (11.3 mL, 11.3 mmol) at a rate maintaining the internal temperature below -89°C. The mixture was stirred for approximately 3 h, as the temperature gradually rose to -77°C, then quenched with methanol (5 mL) and 10% aqueous citric acid (50 mL). After dilution with methylene chloride (200 mL), the mixture was washed with saturated potassium sodium tartrate (100 mL), and the aqueous layer was extracted with methylene chloride (2 x 200 mL). The combined organic layers were washed with brine (300 mL) and the brine wash was further extracted with methylene chloride (100 mL). The organic layers were dried (sodium sulfate), concentrated, and the remnant chromatographed (silica gel, 1-15% ethyl acetate/hexane) to yield 360 mg (18%) of starting material, 1.21 g (60%, 74% based on recovered starting material) of the titled compound as a white crystalline solid (analytical sample recrystallized from hexane/ethyl acetate, mp 162-164°C). ¹H NMR (300 MHz) δ 7.70 (d, J = 9.0 Hz, 1H), 7.46 (d, J = 2.1 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.00 (dd, J = 8.5, 1.8 Hz, 1H), 6.85 (br s, 1H), 6.6 (m, 2H), 6.39 (br s, 1H), 1.01 (s, 9H), 1.00 (s, 9H), 0.25 (s, 6H), 0.25 (s, 6H), ¹³C NMR (125 MHz) δ 156.9, 153.3, 151.7, 139.9, 131.9, 124.5, 123.9, 121.7, 118.8, 113.7, 113.1, 112.7, 108.7, 90.7, 25.1, 25.1, 17.9, -5.2, -5.2, IR (CHCl₃) 3540 cm⁻¹; MS (FD+) m/e 514 (M⁺), Anal. calc'd for C₂₇H₃₈O₄SSi₂: C, 62.98, H, 7.45. Found C, 63.25, H, 7.68, and 260 mg (13%, 16% based on recovered starting material of the diol below

35



40


as an amorphous solid: ¹H NMR (300 MHz, CDCl₃) δ 7.73 (d, J = 8.7 Hz, 1H), 7.29 (d, J = 2.0 Hz, 1H), 7.16 (d, J = 8.2 Hz, 1H), 6.98 (dd, J = 8.7, 2.0 Hz, 1H), 6.5 (m, 3H), 6.30 (br s, 1H), 4.71 (s, 2H), 1.01 (s, 9H), 1.00 (s, 9H), 0.22 (s, 6H), 0.19 (s, 6H), IR (CHCl₃) 3600, 3510 cm⁻¹, MS (FD+) m/e 516 (M⁺), Anal. calc'd. for C₂₇H₄₀O₄SSi₂: C, 62.73, H, 7.82. Found C, 62.49, H, 7.83.

50

55

Preparation 53,9-Bis[(*tert*-butyl(dimethylsilyl)oxy]-6-phenoxy-6-*H*-[1]benzothieno[3,2-c][1]benzopyran


5



To a solution of the product of Preparation 4 (4.52 g, 8.78 mmol) and phenol (4.13 g, 43.9 mmol) in methylene chloride (100 mL) was added anhydrous magnesium sulfate (4.5 g) and the resultant slurry was stirred for 4 h at ambient temperature. The mixture was filtered and concentrated and the residue dissolved in chlorobenzene and reconcentrated *in vacuo* at approximately 70°C. The residue was then dissolved in methylene chloride (300 mL), washed with saturated sodium carbonate (3 x 300 mL) and water (2 x 300 mL), dried (sodium sulfate), and concentrated to yield 5.16 g (99%) of the title compound as an amorphous solid which was used without further purification. ¹H NMR (300 MHz) δ 7.67 (d, J = 8.7 Hz, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.47-7.5 (m, 4H), 7.23 (d, J = 8.4 Hz, 1H), 7.08 (t, J = 7.2 Hz, 1H), 6.99 (dd, J = 8.7, 2.1 Hz, 1H), 6.67 (dd, J = 8.4, 2.3 Hz, 1H), 6.62 (d, J = 2.3 Hz, 1H), 0.99 (s, 9H), 0.96 (s, 9H), 0.24 (s, 6H), 0.21 (s, 6H); ¹³C NMR (125 MHz) δ 156.9, 153.3, 151.7, 139.9, 131.9, 124.5, 123.9, 121.7, 118.8, 113.7, 113.1, 112.7, 108.7, 90.7, 25.1, 25.1, 17.9, -5.2, -5.2, MS (FD+) m/e 590 (M⁺). Anal. calc'd for C₃₃H₄₂O₄SSi₂: C, 67.06; H, 7.18. Found: C, 66.78; H, 6.96.

30 Preparation 63,9-Bis[(*tert*-butyl(dimethylsilyl)oxy]-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-*H*-[1]benzothieno[3,2-c][1]benzopyran

35



50 To a solution of the product of Preparation 5 (4.0 g, 6.7 mmol) in toluene (100 mL) at 0°C was added a 0.5 M THF solution of 4-[2-(1-piperidinyl)ethoxy]phenylmagnesium bromide (prepared from the corresponding bromobenzene and magnesium turnings, catalyzed by iodine in THF, 27 mL, 13.5 mmol). The mixture was allowed to warm to room temperature and stirred for 1.5 h. After quenching with water (300 mL), the mixture was extracted with ethyl acetate (2 x 300 mL), and the organic layer was dried (sodium sulfate) and concentrated. The residue was purified via chromatography (silica gel, 3:1 hexane ethyl acetate, 0.1% ammonium hydroxide) to give 3.85 g (82%) of the title compound as a colorless gummy solid. ¹H NMR (300 MHz) δ 7.45 (s, 1H), 7.2-7.3 (m, 4H), 6.8-6.9 (m, 3H), 6.68 (s, 1H), 6.51 (d, J = 8.1 Hz, 1H), 6.36 (s, 1H), 4.01 (t, J = 6.0 Hz, 2H), 2.62 (t, J = 6.0 Hz, 2H), 2.41 (m, 4H), 1.4-1.6 (m, 4H), 1.3-1.4 (m, 2H), 0.99 (s, 9H), 0.96 (s, 9H), 0.22 (s, 6H), 0.20 (s, 6H); ¹³C NMR (125 MHz) δ 160.3, 157.9, 154.0, 153.5, 141.0, 132.8, 132.6, 130.1, 129.8, 126.1, 124.8, 122.7, 119.4, 115.3, 114.5, 114.2, 114.0, 109.4, 78.2, 66.9, 58.5, 55.6, 26.8,


26 O, 26 O, 25 O, 18 7, -4 3, -4.3, MS (FD) m/e 702 (M+); Anal calc'd for C₄₀H₅₅NO₄SSI₂. C, 68.43; H, 7.90, N, 2.00
Found: C, 68.58; H, 8.00, N, 2.26

Example 1

5

3,9-Dihydroxy-6-[4-(2-(1-piperidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran

10



15

20


To a solution of the Preparation 6 product (3.85 g, 5.5 mmol) in THF (150 mL), was added a 1.0 M THF solution of tetra-n-butylammonium fluoride (TBAF) (27.4 mL, 27.4 mmol). The solution was stirred at ambient temperature for 2 h, then diluted with ethyl acetate (300 mL) and washed with saturated ammonium chloride (300 mL). The aqueous layer was washed with ethyl acetate (150 mL), and the combined organic layers were washed with saturated sodium bicarbonate (300 mL), dried (sodium sulfate), and concentrated. The remnant was purified by chromatography (silica gel, 1:1 hexane ethyl acetate, 10% methanol, 0.1% ammonium hydroxide) to give 2.35 g (90%) of the titled product as a red foam. Crystallization from methanol gave an off-white powder, mp 242–245°C. ¹H NMR (300 MHz) δ 8.58 (br s, 2H), 7.35 (d, J = 2.1 Hz, 1H), 7.26 (d, J = 8.6 Hz, 2H), 7.17 (d, J = 8.2 Hz, 1H), 7.16 (d, J = 8.6 Hz, 1H), 6.84 (d, J = 8.5 Hz, 2H), 6.80 (m, J = 2.2 Hz, 1H), 6.63 (s, 1H), 6.46 (dd, J = 8.2, 2.2 Hz, 1H), 6.35 (d, J = 2.3 Hz, 1H), 4.02 (t, J = 6.0 Hz, 2H), 2.63 (t, J = 6.0 Hz, 2H), 2.42 (m, 4H), 1.4–1.6 (m, 4H), 1.3–1.4 (m, 2H); ¹³C NMR (125 MHz, dimethylformamide-*d*₇) δ 160.2, 159.9, 156.4, 153.2, 140.8, 132.8, 130.9, 129.6, 125.3, 124.6, 122.5, 115.2, 115.1, 112.2, 109.6, 108.8, 108.7, 104.5, 77.6, 66.6, 58.3, 55.3, 26.5, 24.8; HRMS (FAB+) m/e calc'd. for C₂₈H₂₈NO₄S 474.1739 (MH⁺), found 474.1726. Anal calc'd. for C₂₈H₂₇NO₄S·0.8H₂B·C, 68.90; H, 5.92, N, 2.87. Found: C, 68.68; H, 5.76, N, 2.86

35

Example 2

3,9-Dimethoxy-6-[4-(2-(1-piperidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran

40



45

50

A solution of the product of Example 1 (300 mg, 0.633 mmol) in methanol (75 mL) was treated with a solution of diazomethane in ether/ethanol (approximately 16 mmol) at ambient temperature. The mixture was stirred until gas evolution ceased, nitrogen was bubbled through for 10 min to remove excess diazomethane, and the mixture was concentrated. Radial chromatography of the residue (1:1 hexane ethyl acetate, 2% methanol, under an ammonia atmosphere) provided 118 mg (37%) of the title compound as white crystals, mp 134–36. ¹H NMR (300 MHz) δ 7.51 (d, J = 2.2 Hz, 1H), 7.2–7.4 (m, J = 8.6 Hz, 4H), 6.86 (m, 3H), 6.70 (s, 1H), 6.55 (dd, J = 8.4, 2.3 Hz, 1H), 6.41 (d, J = 2.4 Hz, 1H), 4.01 (t, J = 6.0 Hz, 2H), 3.83 (s, 3H), 3.74 (s, 3H), 2.62 (t, J = 6.0 Hz, 2H), 2.40 (m, 4H), 1.4–1.6 (m, 4H).

1 3-1 4 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 160.8, 159.2, 157.1, 152.6, 140.3, 131.6, 131.3, 130.5, 129.1, 124.3, 124.0, 121.7, 114.6, 114.0, 112.8, 107.6, 105.7, 102.3, 77.9, 65.8, 57.8, 55.5, 55.2, 54.9, 25.9, 24.1; MS (FD+) m/e 501 (M^+); Anal. calc'd. for $\text{C}_{30}\text{H}_{31}\text{NO}_4\text{S}$: C, 71.83; H, 6.23, N, 2.79 Found: C, 71.53; H, 6.20, N, 2.84


5 Example 3

3,9-Bis(benzoyloxy)-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H[1]benzothieno[3,2-c] [1]benzopyran

10

15

20



To a solution of the product of Example 1 (200 mg, 0.42 mmol) in methylene chloride (25 mL) at room temperature was added triethylamine (0.18 mL, 1.27 mmol) followed by benzoyl chloride (0.15 mL, 1.27 mmol) via syringe over 10 minutes. The reaction mixture was stirred for 16 hours and then washed with saturated sodium bicarbonate (25 mL) followed by water (25 mL). The organic layer was dried (sodium sulfate) and concentrated, and the residue was purified by radial chromatography (silica gel, 12:12:1 ethyl acetate hexanes:methanol under an ammonia atmosphere) to afford 200 mg (69%) of the title compound as a tan solid: ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 8.1-8.2 (m, 5H), 7.5-7.8 (m, 8H), 7.2-7.3 (m, 3H), 6.9-7.0 (m, 5H), 4.00 (t, $J = 5.5$ Hz, 2H), 2.60 (t, $J = 4.8$ Hz, 2H), 2.38 (m, 4H), 1.4-1.5 (m, 4H), 1.3-1.4 (m, 2H); HRMS (FAB+) m/e calc'd. for $\text{C}_{42}\text{H}_{36}\text{NO}_6\text{S}$ 682.2263 (M^+), found 682.2286


35 Example 4

3,9-Bis(pivaloyloxy)-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H[1]benzothieno[3,2-c] [1]benzopyran

35

40

45




50 According to the procedure of Example 2, the product of Example 1 (200 mg, 0.42 mmol) was reacted with triethylamine (0.18 mL, 1.27 mmol) and pivaloyl chloride (0.16 mL, 1.27 mmol) in methylene chloride (25 mL) to afford 190 mg (70%) of the title compound as a white foam: ^1H NMR (300 MHz, CDCl_3) δ 7.58 (d, $J = 1.7$ Hz, 1H), 7.35 (d, $J = 8.1$ Hz, 1H), 7.26 (d, $J = 9.6$ Hz, 2H), 7.14 (d, $J = 8.7$ Hz, 1H), 6.93 (dd, $J = 8.8, 2.1$ Hz, 1H), 6.83 (d, $J = 8.6$ Hz, 2H), 6.70 (dd, $J = 4.3, 2.1$ Hz, 1H), 6.63 (s, 2H), 4.13 (t, $J = 5.4$ Hz, 2H), 2.83 (m, 2H), 2.58 (m, 4H), 1.66 (m, 4H), 1.46 (m, 2H), 1.37 (s, 9H), 1.33 (s, 9H); MS (FD+) m/e 641 (M^+); HRMS (FAB+) m/e calc'd. for $\text{C}_{38}\text{H}_{44}\text{NO}_6\text{S}$ 642.2889 (M^+), found 642.2848; Anal. calc'd. for $\text{C}_{38}\text{H}_{43}\text{NO}_6\text{S}$: C, 71.11; H, 6.75; N, 2.18 Found: C, 71.86; H, 6.49; N, 2.09

Example 5

3,9-Bis(1-butylsulfonyloxy)-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran

5



20 According to the procedure of Example 2, the product of Example 1 (200 mg, 0.42 mmol) was reacted with triethylamine (0.18 mL, 1.27 mmol) and *n*-butanesulfonyl chloride (0.17 mL, 1.27 mmol) in methylene chloride (25 mL) to afford 120 mg (40%) of the title compound as a clear brown gum. ¹H NMR (300 MHz, CDCl₃) δ 7.77 (s, 1H), 7.38 (d, J = 8.5 Hz, 1H), 7.29 (d, J = 9.5 Hz, 2H), 7.11 (s, 2H), 6.8-6.9 (m, 4H), 6.63 (s, 1H), 4.08 (t, J = 5.4 Hz, 2H), 3.2-3.2 (m, 4H), 2.77 (t, J = 5.4 Hz, 2H), 2.51 (m, 4H), 1.9-2.0 (m, 4H), 1.4-1.6 (m, 10H), 0.9-1.0 (m, 6H), HRMS (FAB+) m/e calc'd. for C₃₈H₄₄NO₈S₃ 714.2229 (MH⁺), found 714.2206.

25


Example 6

30 3,9-Bis(trifluoromethanesulfonyloxy)-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran

35

40

45



50

55

To a solution of the product of Example 1 (500 mg, 1.06 mmol) in THF (25 mL) containing dimethylformamide (2 mL) at room temperature was added triethylamine (0.64 g, 0.69 mL, 6.36 mmol) followed by *N*-phenyltrifluoromethanesulfonimide (0.83 g, 2.33 mmol). The reaction mixture was stirred for 12 hours, warmed to 60°C, and additional *N*-phenyltrifluoromethanesulfonimide (0.30 g, 0.85 mmol) was added. After 30 min, the reaction mixture was cooled to ambient temperature and concentrated, and the residue was purified by radial chromatography (silica gel, 1:1 hexane ethyl acetate, 1% methanol under an ammonia atmosphere) to afford 780 mg (100%) of the title compound as a white foam. ¹H NMR (300 MHz, methanol-*d*₄) δ 7.63 (d, J = 8.8 Hz, 1H), 7.56 (d, J = 2.5 Hz, 1H), 7.13 (dd, J = 8.8, 2.7 Hz, 1H), 7.03 (d, J = 8.8 Hz, 2H), 6.80 (d, J = 8.9 Hz, 2H), 6.49 (d, J = 2.5 Hz, 1H), 6.39 (d, J = 8.7 Hz, 1H), 6.05 (dd, J = 8.7, 2.6 Hz, 1H), 4.00 (t, J = 5.5 Hz, 2H), 2.67 (m, 2H), 2.45 (m, 4H), 1.4-1.6 (m, 4H), 1.3-1.4 (m, 2H); ¹³C NMR (125 MHz) δ 159.8, 152.8, 150.2, 146.9, 140.4, 136.6, 130.5, 129.2, 127.3, 125.3, 123.4, 119.2, 118.9, 116.3, 114.7, 114.6, 110.4, 77.7, 66.0, 57.6, 54.7, 25.8, 24.0, MS (FD) m/e 737 (M⁺); Anal. calc'd for C₃₀H₂₅F₆NO₈S₃: C, 48.84; H, 3.42; N, 1.90. Found: C, 49.05; H, 3.71; N, 1.72.


Example 7

6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H[1]benzothieno[3,2-c][1]benzopyran

5

10

15



A solution of the product of Example 6 (780 mg, 1.06 mmol), palladium(II) acetate (42 mg, 0.19 mmol), 1,2-bis(diphenylphosphinopropane (149 mg, 0.36 mmol), formic acid (0.6 mL), and triethylamine (3.0 mL) in anhydrous dimethylformamide (40 mL) was stirred at ambient temperature for 4 d. After concentration, the residue was subjected chromatography (silica gel, 1:1 hexane:ethylacetate, 2-10% methanol, 0.1% ammonium hydroxide). Product containing fractions were concentrated, partitioned between methylene chloride (100 mL) and saturated sodium bicarbonate (100 mL), and the aqueous layer extracted with methylene chloride (50 mL). The combined organic extracts were dried (sodium sulfate), concentrated, and the residue purified by chromatography (silica gel, 1:1 hexane:ethylacetate, 2-10% methanol, 0.1% ammonium hydroxide) to give 267 mg (57%) of the title compound as an oil which gave a white, crystalline solid, mp 107°C, upon trituration with ether/hexane. ¹H NMR (300 MHz, CDCl₃) δ 7.86 (d, J = 7.4 Hz, 1H), 7.40 (m, 1H), 7.1-7.3 (m, 6H), 6.97 (t, J = 7.3 Hz, 1H), 6.89 (d, J = 8.1 Hz, 1H), 6.84 (d, J = 8.6 Hz, 2H), 6.66 (s, 1H), 4.07 (t, J = 6.1 Hz, 2H), 2.75 (t, J = 6.1 Hz, 2H), 2.49 (m, 4H), 1.5-1.7 (m, 4H), 1.4-1.5 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 159.1, 151.6, 139.3, 137.1, 133.0, 131.5, 129.8, 129.1, 126.8, 124.6, 124.4, 123.7, 122.6, 121.5, 121.5, 119.3, 116.9, 114.6, 77.6, 65.7, 57.7, 54.9, 25.8, 24.0; MS (FD+) m/e 441 (M+); Anal. calc'd for C₂₈H₂₇NO₂S: C, 76.15; H, 6.17; N, 3.17. Found: C, 75.93; H, 6.44; N, 3.01.


Preparation 7

3,9-Bis[(tert-butyldimethylsilyl)oxy]-6-[4-hydroxyphenyl]-6-H[1]benzothieno[3,2-c][1]benzopyran

35

40

45




50 To a solution of the product of Preparation 5 (3.0 g, 5.08 mmol) in toluene (150 mL) at 0°C was added a 0.4 M THF solution of 4-(trimethylsilyloxy)phenylmagnesium bromide (prepared from the corresponding bromobenzene and magnesium turnings, catalyzed by iodine in THF, 25.4 mL, 10.16 mmol). The mixture was allowed to warm to room temperature and stirred for 1.5 h. After dilution with ether (250 mL), the mixture was quenched with saturated ammonium chloride (250 mL) and the organic layer was dried (sodium sulfate) and concentrated. The residue was slurried in methanol (100 mL) and ether was added until the mixture was homogeneous. The solution was cooled to 0°C and treated with anhydrous potassium carbonate (3 g) for 15 min. After dilution with ether (250 mL), the mixture was filtered through Celite, washed with saturated ammonium chloride, and the aqueous layer was extracted with additional ether (100 mL). The combined organic layers were dried (sodium sulfate), concentrated, and the residue purified by chro-

matography (silica gel, 1:1 hexane ethyl acetate). Recrystallization from hexane provided 2.6 g (87%) of the title compound as a light pink solid, mp 174–175°C. ¹H NMR (300 MHz) δ 8.49 (s, 1H), 7.44 (d, J = 2.2 Hz, 1H), 7.3–7.4 (m, 4H), 6.83 (dd, J = 8.6, 2.3 Hz, 1H), 6.76 (d, J = 8.5 Hz, 2H), 6.65 (s, 1H), 6.50 (dd, J = 8.2, 2.3 Hz, 1H), 6.36 (d, J = 2.3 Hz, 1H), 0.98 (s, 9H), 0.95 (s, 9H), 0.21 (s, 6H), 0.20 (s, 6H); ¹³C NMR (125 MHz) δ 158.7, 157.8, 153.9, 153.5, 140.9, 132.7, 131.6, 131.1, 129.9, 126.1, 124.7, 122.7, 119.3, 116.1, 114.4, 114.0, 113.9, 109.3, 78.3, 26.0, 25.9, 18.7, -4.3; IR (CHCl₃) 3590, 3310 cm⁻¹; MS (FD+) m/e 590 (M⁺); Anal. calcd for C₃₃H₄₂O₄SSi₂: C, 67.07; H, 7.16. Found: C, 66.79; H, 7.05.

Preparation 8


10 **3,9-Bis[(tert-butyldimethylsilyl)oxy]-6-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c][1]benzopyran**



A toluene solution of the product of Preparation 7 (400 mg, 0.68 mmol), triphenylphosphine (708 mg, 2.7 mmol), and 1-(2-hydroxyethyl)pyrrolidine (390 mg, 3.39 mmol) was treated with diethyl azodicarboxylate (DEAD) (470 mg, 425 mL, 2.7 mmol) at room temperature and stirred for 2 h. The mixture was then diluted with ether (100 mL), washed with saturated ammonium chloride (100 mL), and the aqueous layer washed with additional ether (50 mL). The combined organic layers were dried (sodium sulfate), concentrated, and the residual triphenylphosphine oxide precipitated from hexane. The hexane mother liquor was concentrated and the residue purified by chromatography (silica gel, 1:1 hexane:ethyl acetate, 3–5% methanol, 0.1% ammonium hydroxide) to give 359 mg (77%) of the title compound as a colorless oil. ¹H NMR (300 MHz) δ 7.45 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 8.6 Hz, 2H), 7.22 (m, 2H), 6.85 (d, 8.6 Hz, 2H), 6.83 (dd, J = 8.6, 2.3 Hz, 1H), 6.68 (s, 1H), 6.50 (dd, J = 8.3, 2.2 Hz, 1H), 6.36 (d, 2.2 Hz, 1H), 4.03 (t, J = 6.0 Hz, 2H), 2.77 (t, J = 6.0 Hz, 2H), 2.50 (m, 4H), 1.67 (m, 4H), 0.98 (s, 9H), 0.95 (s, 9H), 0.21 (s, 6H), 0.20 (s, 6H); ¹³C NMR (125 MHz) δ 160.1, 157.8, 153.9, 153.4, 140.9, 132.7, 132.5, 131.1, 129.8, 125.9, 124.7, 122.6, 119.3, 115.1, 114.4, 114.1, 113.9, 109.4, 78.1, 67.7, 55.2, 54.9, 26.0, 25.9, 24.0, 18.6, -4.3. MS (FD+) m/e 687 (M⁺); Anal. calcd for C₃₉H₅₃NO₄SSi₂: C, 68.06; H, 7.78; N, 2.04. Found: C, 67.94; H, 7.61; N, 2.21.

Example 8

45 **3,9-Dihydroxy-6-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c][1]benzopyran**




By the procedure described for Example 1, the product of Preparation 8 (331 mg, 0.48 mmol) was reacted with 1.0 M TBAF in THF (2.4 mmol) to give, after radial chromatography (silica gel, 1:1 hexane/ethyl acetate, 30% methanol, under an ammonia atmosphere) 200 mg (91%) of the title compound as a white solid, mp 237-240°C. ¹H NMR (300 MHz, dimethylformamide-*d*₇) δ 10.05 (br, 2H), 7.45 (d, J = 2.0 Hz, 1H), 7.30 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.6 Hz, 1H), 7.19 (d, J = 8.2 Hz, 1H), 6.91 (d, J = 8.7 Hz, 2H), 6.86 (dd, J = 8.9, 2.2 Hz, 1H), 6.74 (s, 1H), 6.51 (dd, J = 8.2, 2.1 Hz, 1H), 6.40 (d, J = 2.1 Hz, 1H), 4.14 (t, J = 5.6 Hz, 2H), 2.96 (t, J = 5.5 Hz, 2H), 2.6-2.8 (m, 4H), 1.6-1.8 (m, 4H). ¹³C NMR (125 MHz, dimethylformamide-*d*₇) δ 160.2, 159.6, 156.4, 153.2, 140.8, 133.0, 130.8, 129.6, 125.2, 124.6, 122.4, 115.3, 115.1, 112.2, 109.7, 108.8, 104.5, 77.6, 66.8, 54.8, 54.7, 23.8. IR (KBr) 3286 cm⁻¹. HRMS (FAB+) m/e calc'd. for C₂₇H₂₆NO₄S 460.1583 (M⁺), found 460.1572. Anal. calc'd. for C₂₇H₂₅NO₄S·0.5H₂O: C, 69.20; H, 5.60; N, 2.99. Found: C, 69.13; H, 5.31; N, 2.58.

Preparation 9

15 **3,9-Bis[(tert-butyldimethylsilyloxy)-6-[4-(2-dimethylaminoethoxy)phenyl]-6-*H*-[1]benzothieno[3,2-c][1]benzopyran**

20



25

30

35

40


By the method described in Preparation 8, the product of Preparation 7 (450 mg, 0.76 mmol), triphenylphosphine (799 mg, 3.1 mmol), and *N,N*-dimethylethanolamine (340 mg, 3.81 mL, 3.81 mmol) were reacted with diethyl azodicarboxylate (DEAD) (531 mg, 480 mL, 3.1 mmol) in toluene (30 mL). Chromatography (silica gel, 1:1 hexane/ethyl acetate, 3% methanol, 0.1% ammonium hydroxide) provided 357 mg (71%) of the title compound as a white foam: ¹H NMR (300 MHz) δ 7.45 (d, J = 2.1 Hz, 1H), 7.27 (d, J = 8.6 Hz, 2H), 7.24 (m, 2H), 6.83 (m, 3H), 6.67 (s, 1H), 6.50 (dd, J = 8.2, 2.2 Hz, 1H), 6.36 (d, 2.2 Hz, 1H), 4.00 (t, J = 5.9 Hz, 2H), 2.60 (t, J = 5.9 Hz, 2H), 2.20 (s, 6H), 0.98 (s, 9H), 0.95 (s, 9H), 0.21 (s, 6H), 0.20 (s, 6H). ¹³C NMR (125 MHz) δ 160.1, 157.8, 153.9, 153.4, 141.0, 132.7, 132.6, 131.2, 129.8, 126.0, 124.7, 122.7, 119.4, 115.2, 114.4, 114.1, 113.9, 109.4, 78.1, 67.0, 58.7, 46.0, 26.0, 25.9, 18.6, -4.3. MS (FD+) m/e 661.5 (M⁺). Anal. calc'd. for C₃₇H₅₁NO₄SSi₂: C, 67.11; H, 7.78; N, 2.12. Found: C, 67.38; H, 7.52; N, 2.09.

45

Example 9

3,9-Dihydroxy-6-[4-(2-dimethylaminoethoxy)phenyl]-6-*H*-[1]benzothieno[3,2-c][1]benzopyran

50




55

By the procedure described for Example 1, the product of Preparation 9 (328 mg, 0.50 mmol) was reacted with 1.0 M

TBAF in THF (2.5 mmol) to give, after radial chromatography (silica gel, 1:1 hexane ethyl acetate, 30% methanol, under an ammonia atmosphere) 212 mg (99%) of the title compound, which crystallized from carbon tetrachloride/acetone as a pink solid, mp 130-140°C; ¹H NMR (300 MHz) δ 7.34 (d, J = 2.1 Hz, 1H), 7.25 (d, J = 8.6 Hz, 2H), 7.15 (m, 2H), 6.9-7.0 (m, 3H), 6.62 (s, 1H), 6.45 (dd, J = 8.3, 2.3 Hz, 1H), 6.34 (d, J = 2.2 Hz, 1H), 4.01 (t, J = 5.8 Hz, 2H).
 5 2.64 (t, J = 5.8 Hz, 2H), 2.30 (s, 6H); ¹³C NMR (125 MHz) δ 160.0, 159.8, 156.0, 153.5, 141.1, 133.0, 131.4, 130.2, 129.8, 125.3, 124.8, 122.6, 115.3, 115.2, 112.7, 109.7, 109.0, 104.8, 78.0, 66.6, 58.6, 45.8. IR (KBr) 3300 cm⁻¹, HRMS (FAB+) m/e calc'd for C₂₅H₂₄NO₄S 434.1426 (MH⁺), found 434.1440; Anal calc'd. for C₂₅H₂₃NO₄S·0.4CCl₄: C, 61.62; H, 4.69; N, 2.83. Found C, 60.93; H, 4.73; N, 2.95

10 **Preparation 10**

3,9-Bis[(tert-butyldimethylsilyloxy]-6-[4-[2-(2-oxo-1-pyrrolidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c][1]benzopyran




30 By the method described in Preparation 8, the product of Preparation 7 (450 mg, 0.76 mmol), triphenylphosphine (799 mg, 3.1 mmol), and 1-(2-hydroxyethyl)-2-pyrrolidinone (492 mg, 431 mL, 3.81 mmol) were reacted with diethyl azodi-carboxylate (DEAD) (531 mg, 480 mL, 3.1 mmol) in toluene (30 mL). Chromatography (silica gel, 1:1 hexane ethyl acetate) provided 368 mg (69%) of the title compound as a white foam: ¹H NMR (300 MHz) δ 7.45 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 8.7 Hz, 2H), 7.23 (d, J = 8.2 Hz, 1H), 7.22 (d, J = 8.6 Hz, 1H), 6.88 (m, 3H), 6.69 (s, 1H), 6.51 (dd, J = 8.5, 2.5 Hz, 1H), 6.36 (d, 2.3 Hz, 1H), 4.05 (t, J = 5.4 Hz, 2H), 3.54 (t, J = 5.4 Hz, 2H), 3.46 (t, J = 7.0 Hz, 2H), 2.15 (t, J = 8.0 Hz, 2H), 1.91 (m, 2H), 0.98 (s, 9H), 0.95 (s, 9H), 0.21 (s, 6H), 0.20 (s, 6H); ¹³C NMR (125 MHz) δ 175.0, 160.1, 158.1, 154.2, 153.6, 141.2, 133.2, 133.0, 131.4, 130.1, 126.2, 125.0, 122.9, 119.6, 115.5, 114.6, 114.4, 114.2, 109.6, 78.3, 67.0, 48.7, 42.7, 31.2, 26.2, 26.2, 18.9, -4.1. IR (CHCl₃) 1673 cm⁻¹, HRMS (FAB+) m/e calc'd. for C₃₉H₅₁NO₅SSi₂ 701.3027 (M⁺), found 701.3039

35

40

Example 10

3,9-Dihydroxy-6-[4-[2-(2-oxo-1-pyrrolidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c][1]benzopyran




By the procedure described for Example 1, the product of Preparation 10 (331 mg, 0.47 mmol) was reacted with 1.0 M TBAF in THF (2.4 mmol) to give, after radial chromatography (silica gel, 1:1 hexane ethyl acetate, 20% methanol,

under an ammonia atmosphere) and recrystallization from acetone 161 mg (72%) of the title compound as a red solid, mp 150-160°C. ^1H NMR (300 MHz, methanol- d_4) δ 7.21 (m, 3H), 7.11 (d, J = 8.3 Hz, 1H), 7.02 (d, J = 8.7 Hz, 1H), 6.80 (d, J = 8.6 Hz, 2H), 6.71 (dd, J = 8.6, 2.2 Hz, 1H), 6.51 (s, 1H), 6.37 (dd, J = 8.2, 2.3 Hz, 1H), 6.25 (d, J = 2.3 Hz, 1H), 4.04 (t, J = 5.2 Hz, 2H), 3.57 (t, J = 5.2 Hz, 2H), 3.48 (t, J = 7.1 Hz, 2H), 2.28 (t, J = 8.1 Hz, 2H), 1.91 (quintet, J = 7.5 Hz, 2H). ^{13}C NMR (125 MHz, methanol- d_4) δ 178.0, 160.2, 160.0, 156.2, 153.9, 141.7, 133.7, 131.9, 130.9, 130.3, 125.6, 125.0, 122.7, 115.6, 115.4, 113.4, 109.8, 109.0, 104.9, 78.6, 66.6, 43.4, 31.8, 30.7, 18.9; IR (CHCl₃) 1680 cm⁻¹; MS (FD+) m/e 474 (MH⁺); Anal. calc'd for C₂₇H₂₃NO₅S·(CH₃)₂CO: C, 67.77; H, 5.51; N, 2.64. Found: C, 67.92; H, 5.56; N, 2.59.

10 Example 10a

3,9-Dihydroxy-6-[4-(2-diethylaminoethoxy)phenyl]-6-H[1]benzothieno[3,2-c][1]benzopyran

15



20

25

By the procedure described for Example 1, the product of Preparation 11 (458 mg, 0.66 mmol) was reacted with 1.0 M TBAF in THF (3.3 mmol) to give, after radial chromatography (silica gel, 1:1 hexane ethyl acetate, 10-20% methanol, under an ammonia atmosphere) and crystallization from acetone/ether 296 mg (72%) of the title compound as a red solid, mp 118-123°C. ^1H NMR (300 MHz) δ 7.35 (d, J = 2.1 Hz, 1H), 7.26 (d, J = 8.6 Hz, 2H), 7.16 (d, J = 6.1 Hz, 1H), 7.13 (d, J = 8.5 Hz, 1H), 6.81 (m, 3H), 6.62 (s, 1H), 6.45 (dd, J = 8.3, 2.3 Hz, 1H), 6.35 (d, J = 2.2 Hz, 1H), 3.98 (t, J = 6.2 Hz, 2H), 2.78 (t, J = 6.2 Hz, 2H), 2.56 (q, J = 7.1 Hz, 4H), 0.97 (t, J = 7.1 Hz, 6H). ^{13}C NMR (75 MHz) δ 160.2, 159.7, 155.9, 153.5, 141.1, 132.9, 131.5, 130.2, 129.9, 125.4, 124.8, 122.7, 115.2, 112.8, 109.6, 108.9, 104.8, 78.1, 67.5, 52.6, 48.3, 12.4; IR (KBr) 3311 cm⁻¹; MS (FD+) m/e 462 (MH⁺); Anal. calc'd. for C₂₇H₂₇NO₄S: C, 70.04; H, 6.13; N, 3.04. Found C, 70.26, H, 5.90; N, 3.03.


Example 10b

3,9-Dihydroxy-6-[4-[2-(1-morpholinyl)ethoxy]phenyl]-6-H[1]benzothieno[3,2-c][1]benzopyran

40

45

50



By the procedure described for Example 1, the product of Preparation 12 (521 mg, 0.74 mmol) was reacted with 1.0 M TBAF in THF (3.7 mmol) to give, after radial chromatography (silica gel, 1:1 hexane:ethyl acetate, 15% methanol, under an ammonia atmosphere) and crystallization from acetone/ether 286 mg (81%) of the title compound as a red solid, mp 147-153°C. ^1H NMR (300 MHz) δ 7.35 (d, J = 2.1 Hz, 1H), 7.25 (d, J = 8.6 Hz, 2H), 7.16 (d, J = 8.3 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 6.81 (m, 3H), 6.62 (s, 1H), 6.46 (dd, J = 8.2, 2.2 Hz, 1H), 6.35 (d, J = 2.2 Hz, 1H), 4.04 (t, J = 7.5 Hz, 2H), 3.57 (t, J = 5.2 Hz, 2H), 3.48 (t, J = 7.1 Hz, 2H), 2.28 (t, J = 8.1 Hz, 2H), 1.91 (quintet, J = 6.2 Hz, 2H). ^{13}C NMR (75 MHz) δ 160.2, 159.7, 155.9, 153.5, 141.1, 132.9, 131.5, 130.2, 129.9, 125.4, 124.8, 122.7, 115.2, 112.8, 109.6, 108.9, 104.8, 78.1, 67.5, 52.6, 48.3, 12.4; IR (KBr) 3311 cm⁻¹; MS (FD+) m/e 462 (MH⁺); Anal. calc'd. for C₂₇H₂₇NO₄S: C, 70.04; H, 6.13; N, 3.04. Found C, 70.26, H, 5.90; N, 3.03.


= 5.7 Hz, 2H), 3.56 (t, J = 4.7 Hz, 4H), 2.68 (t, J = 5.7 Hz, 2H), 2.47 (t, J = 4.3 Hz, 4H), ^{13}C NMR (75 MHz) δ 160.0, 159.7, 155.9, 153.5, 141.1, 132.9, 131.4, 129.8, 129.7, 125.4, 124.8, 122.6, 115.2, 112.8, 109.6, 108.9, 104.7, 78.0, 67.2, 66.5, 58.1, 54.7, IR (KBr) 3471 cm $^{-1}$; MS (FD+) m/e 475 (MH $^+$); Anal. calc'd for $\text{C}_{27}\text{H}_{25}\text{NO}_5\text{S}\cdot 0.25\text{H}_2\text{O}$: C, 67.54; H, 5.36; N, 2.92. Found: C, 67.58; H, 5.51; N, 2.57

5

Preparation 12a

6a,11a-Dihydro-9-methoxy-6-H-[1]benzothieno[3,2-c][1]benzopyran-6-one

10



15

20

To a stirred solution of 6-methoxythianaphthen-2-one (52.6 g, 290 mmol) in a mixture of ethanol (260 mL) and methylene chloride (130 mL) was added triethylamine (2.0 mL, 14.8 mmol) followed by salicylaldehyde (32 mL, 300 mmol) at room temperature. After 1 h, a solid began to precipitate and stirring was continued for 3.5 h. The mixture was then diluted with cold hexane and filtered to yield 68.3 g (83%) of the title product as a powdery white solid, pure by ^1H -NMR analysis. ^1H NMR (300 MHz, CDCl_3) δ 7.45 (d, J = 7.5 Hz, 1H), 7.33 (m, 2H), 7.17 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 6.77 (d, J = 2.4 Hz, 1H), 6.69 (dd, J = 2.4, 8.5 Hz, 1H), 5.25 (d, J = 7.4 Hz, 1H), 4.37 (d, J = 7.3 Hz, 1H), 3.77 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 166.4, 160.7, 150.8, 141.4, 130.1, 129.0, 127.7, 127.0, 124.9, 119.5, 117.2, 111.2, 108.3, 55.5, 50.6, 49.6, IR (CHCl_3) 1766 cm $^{-1}$; MS (FD) m/e 284 (M $^+$); Anal. calc'd for $\text{C}_{16}\text{H}_{12}\text{O}_3\text{S}$: C, 67.59; H, 4.26. Found: C, 67.77; H, 4.24


25

Preparation 12b

9-Methoxy-6-H-[1]benzothieno[3,2-c][1]benzopyran-6-one

30

40



45


A mixture of the product of Preparation 12a (14.0 g, 49 mmol) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (11.6 g, 51 mmol) in dichloroethane (350 mL) was heated briefly to reflux, inducing the formation of a precipitate. The mixture was filtered hot, rinsing the precipitate with methylene chloride, and the mother liquor concentrated *in vacuo*. The crude product was then rinsed several times with acetone and dried *in vacuo* to provide 12.6 g (91%) of the title product as a white fluffy solid. ^1H NMR (300 MHz, CDCl_3) δ 8.55 (d, J = 8.9 Hz, 1H), 7.70 (dd, J = 1.2, 8.0 Hz, 1H), 7.4-7.6 (m, 2H), 7.33 (m, 2H), 7.13 (dd, J = 2.3, 8.9 Hz, 1H), 3.91 (s, 3H); IR (CHCl_3) 1722 cm $^{-1}$; MS (FD) m/e 282 (M $^+$); Anal. calc'd for $\text{C}_{16}\text{H}_{10}\text{O}_3\text{S}$: C, 68.07; H, 3.57. Found: C, 67.80; H, 3.53.

55

Preparation 12c**9-(*t*-Butyldimethylsilyl)oxy-6-*H*-[1]benzothieno[3,2-*c*] [1]benzopyran-6-one**

5

10



15

To a mechanically stirred slurry of the product of Preparation 12b (9.0 g, 32 mmol) in methylene chloride (235 mL) was added ethanethiol (5.9 mL, 80 mmol) followed by aluminum chloride (15.8 g, 120 mmol), portionwise. The reaction mixture was stirred at ambient temperature for 1 h, then cooled to 0°C and quenched cautiously with tetrahydrofuran (THF) followed by saturated sodium bicarbonate. The mixture was diluted with THF, the layers separated, and the aqueous layer was washed several times with THF. The combined organic layers were dried (sodium sulfate) and concentrated to yield 7.4 g (86%) of crude phenol as an off-white, slightly pink solid, which was used without further purification

20

25

The crude product was slurried in methylene chloride (200 mL) and treated with triethylamine (19.1 mL, 140 mmol) and *tert*-butyldimethylsilyl chloride (10.4 g, 69 mmol). The mixture was stirred at ambient temperature overnight, during which it became homogeneous. After dilution with hexane, the mixture was washed two times with brine. The organic layer was dried (sodium sulfate), concentrated, and the residue recrystallized from hexane to provide 9.8 g (80%) of the title compound as a fluffy white solid. ¹H NMR (300 MHz, CDCl₃) δ 8.55 (d, J = 8.5 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.4-7.6 (m, 2H), 7.34 (m, 2H), 7.08 (dd, J = 2.2, 8.8 Hz, 1H), 1.02 (s, 9H), 0.26 (s, 6H); IR (CHCl₃) 1717 cm⁻¹; MS (FD) m/e 382 (M⁺). Anal. calc'd for C₂₁H₂₂O₃SSi: C, 65.93, H, 5.80. Found: C, 66.23, H, 5.84


30

Preparation 12d**9-(*t*-Butyldimethylsilyl)oxy-6-*H*-[1]benzothieno[3,2-*c*] [1]benzopyran-6-ol**

35

40

45



55


A solution of the product from Preparation 12c (3.5 g, 9.1 mmol) in toluene (490 mL) was cooled to -78°C and treated dropwise with a 1.0 M toluene solution of diisobutylaluminum hydride (11.0 mL, 11 mmol) at a rate maintaining the internal temperature below -70°C. The mixture was stirred for approximately 4 h, then quenched with methanol (14 mL), 10% aqueous citric acid (140 mL), and water (315 mL). The aqueous layer was extracted three times with methylene chloride (560 mL). The organic layers were dried (sodium sulfate), concentrated, and the remnant chromatographed (silica gel, gradient of 2% ethyl acetate in hexane to 20% ethyl acetate in hexane) to yield 1.7 g (49%) of the title compound as a white crystalline solid. ¹H NMR (300 MHz) δ 7.77 (d, J = 8.6 Hz, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.42 (m, 1H), 7.28 (m, 1H), 7.05 (m, 2H), 6.89 (m, 1H), 6.46 (m, 1H), 1.02 (s, 9H), 0.26 (s, 6H); IR (CHCl₃) 2959, 2932, 2861, 1612, 1598 cm⁻¹; MS (FD) m/e 384 (M⁺). Anal. calc'd for C₂₁H₂₄O₃SSi: C, 65.59, H, 6.29. Found: C, 65.51, H, 6.32.

Preparation 12e**9-(*t*-Butyldimethylsilyloxy)oxy-6-phenoxy-6-H-[1]benzothieno[3,2-c] [1]benzopyran**

5

10

15



The product of Preparation 12d (1.5 g, 3.9 mmol) and phenol (2.7 g, 29 mmol) were dissolved in chlorobenzene (50 mL) and the mixture was stirred for 3.5 h at reflux. The mixture was concentrated and residue redissolved in chlorobenzene and reconcentrated *in vacuo* at approximately 70°C. The residue was then dissolved in diethyl ether, washed three times with saturated sodium carbonate, water and brine. The organic layer was dried (sodium sulfate) and concentrated to yield 1.7 g (93%) of the title compound as a fluffy white solid which was used without further purification: the ¹H NMR spectrum (300 MHz) was consistent with the structure.

Example 10c


25

9-Hydroxy-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran

30

35

40




To a solution of the product of Preparation 12e (1.7 g, 3.6 mmol) in toluene (50 mL) at 0°C was added a 0.2 M THF solution of 4-[2-(1-piperidinyl)ethoxy]phenylmagnesium bromide (prepared from the corresponding bromobenzene and magnesium turnings, catalyzed by iodine in THF, 45.3 mL, 9.1 mmol). The mixture was allowed to warm to room temperature and stirred for 14 h. After quenching with water, the mixture was extracted three times with methylene chloride, and the organic layer was dried (sodium sulfate) and concentrated. The remnant was purified via chromatography (silica gel, hexane:ethyl acetate) to give 2.6 g (126%) of the partially purified silylated product.

To a solution of the partially purified product (2.6 g, 3.6 mmol) in THF (40 mL), was added a 1.0 M THF solution of tetra-*n*-butylammonium fluoride (TBAF) (5.0 mL, 5.0 mmol). The solution was stirred at ambient temperature for 10 min, then diluted with ethyl acetate and washed five times with saturated sodium bicarbonate and brine. The organic layers were dried (sodium sulfate) and concentrated. The remnant was purified via chromatography (silica gel, 1:1 hexane:ethyl acetate, 0-10% methanol, 0.1% ammonium hydroxide) to give 0.93 g (56%) of the title compound as a white fluffy solid: ¹H NMR (300 MHz) δ 6.7-7.4 (m, 12H), 4.02 (t, J = 6.0 Hz, 2H), 2.63 (t, J = 6.0 Hz, 2H), 2.41 (m, 4H), 1.49 (m, 4H), 1.37 (m, 2H); IR (KBr) 2934, 1609 cm⁻¹; MS (FD) m/e 457 (M⁺), HRMS (FAB) m/e calc'd for C₂₈H₂₈NO₃S (MH⁺): 458.1790 Found: 458.1798; Anal. calc'd for C₂₈H₂₇NO₃S·0.5H₂O: C, 72.08; H, 6.05, N, 3.00 Found: C, 71.97, H, 6.04, N, 3.06.

Preparation 12f**3-(*t*-Butyldimethylsilyl)oxy-6-*H*-[1]benzothieno[3,2-*c*] [1]benzopyran-6-one**

5

10



- 15 To a mechanically stirred slurry of 3-Methoxy-6-*H*-[1]benzothieno[3,2-*c*] [1]benzopyran-6-one (*Journal of Organic Chemistry*, **40**, 3169 (1975)) (1.0 g, 3.6 mmol) in methylene chloride (30 mL) was added ethanethiol (1.4 mL, 18.0 mmol) followed by aluminum chloride (1.6 g, 12 mmol), portionwise. The reaction mixture was stirred at ambient temperature for 1.5 h, then cooled to 0°C and quenched cautiously with tetrahydrofuran (THF) followed by saturated sodium bicarbonate. The mixture was diluted with THF, the layers separated, and the aqueous layer was washed several times with THF. The combined organic layers were dried (sodium sulfate) and concentrated to yield the crude phenol, which was used without further purification.


20 The crude product was slurried in methylene chloride (30 mL) and treated with triethylamine (2.5 mL, 18 mmol) and *tert*-butyldimethylsilyl chloride (1.3 g, 9.0 mmol). The mixture was stirred at ambient temperature overnight, during which it became homogeneous. After dilution with hexane, the mixture was washed two times with brine. The organic 25 layer was dried (sodium sulfate), concentrated, and the residue purified by chromatography (silica gel, hexane-4:1 hexane:ethyl acetate) to provide 0.95 g (69%) of the title compound as a fluffy white solid. ¹H NMR (300 MHz, acetone-d₆) δ 5.7 (d, J = 7.8 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.5-7.7 (m, 2H), 6.99 (m, 2H), 1.03 (s, 9H), 0.33 (s, 6H); IR (CHCl₃) 1716 cm⁻¹; MS (FD) m/e 382 (M⁺); Anal. calc'd for C₂₁H₂₂O₃SSi: C, 65.93; H, 5.80. Found C, 66.11; H, 5.83

30

Preparation 12g**3-(*t*-Butyldimethylsilyl)oxy-6-*H*-[1]benzothieno[3,2-*c*] [1]benzopyran-6-ol**

35

40




- 45 A solution of the product from Preparation 12f (5.0 g, 13 mmol) in toluene (700 mL) was cooled to -78°C and treated dropwise with a 1.0 M toluene solution of diisobutylaluminum hydride (15.7 mL, 15.7 mmol) at a rate maintaining the internal temperature below -70°C. The mixture was stirred for approximately 4 h, then quenched with methanol (20 mL), 10% aqueous citric acid (200 mL), and water (450 mL). The aqueous layer was extracted three times with methylene chloride (800 mL). The organic layers were dried (sodium sulfate), concentrated, and the remnant chromatographed (silica gel, gradient of 2% ethyl acetate in hexane to 20% ethyl acetate in hexane) to yield 1.7 g (45%) of the 50 title compound as a white fluffy solid: ¹H NMR (300 MHz) δ 7.96 (d, J = 7.7 Hz, 1H), 7.83 (d, J = 6.7 Hz, 1H), 7.3-7.8 (m, 3H), 6.91 (m, 1H), 6.62 (m, 2H), 1.00 (s, 9H), 0.26 (s, 6H); IR (CHCl₃) 2958, 2932, 2861, 1616, 1594 cm⁻¹; MS (FD) m/e 384 (M⁺); Anal. calc'd for C₂₁H₂₄O₃SSi: C, 65.59; H, 6.29. Found C, 65.31; H, 6.18.

55

Preparation 12h3-(*t*-Butyldimethylsilyl)oxy-6-*H*-[1]benzothieno[3,2-*c*] [1]benzopyran

5

10



15 The product of Preparation 12g (0.09 g, 0.24 mmol) and phenol (0.25 g, 2.6 mmol) were dissolved in chlorobenzene (10 mL) and the mixture was stirred for 3 h at 100°C. The mixture was concentrated and residue redissolved in chlorobenzene and reconcentrated *in vacuo* at approximately 70°C. The residue was then dissolved in diethyl ether, washed five times with saturated sodium carbonate, water and brine. The organic layer was dried (sodium sulfate) and concentrated to yield 0.11 g (100%) of the title compound as a fluffy white solid which was used without further purification.


20 The ¹H NMR spectrum (300 MHz) was consistent with the structure

Example 10d3-Hydroxy-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-*H*-[1]benzothieno[3,2-*c*] [1]benzopyran

25

30

35



40 To a solution of the product of Preparation 12h (0.28 g, 0.61 mmol) in toluene (20 mL) at 0°C was added a 0.2 M THF solution of 4-[2-(1-piperidinyl)ethoxy]phenylmagnesium bromide (prepared from the corresponding bromobenzene and magnesium turnings, catalyzed by iodine in THF, 7.6 mL, 1.5 mmol). The mixture was allowed to warm to room temperature and stirred for 1 h. After quenching with water, the mixture was extracted six times with methylene chloride, and the organic layer was dried (sodium sulfate) and concentrated. The remnant was purified via chromatography (silica gel, 4:1:1 hexane:ethyl acetate) to give 0.41 g (119%) of the partially purified silylated product.

45 To a solution of the partially purified product (0.41 g, 0.72 mmol) in THF (10 mL), was added a 1.0 M THF solution of tetra-n-butylammonium fluoride (TBAF) (0.67 mL, 0.67 mmol). The solution was stirred at ambient temperature for 10 min, then diluted with ethyl acetate and washed three times with saturated sodium bicarbonate and brine. The organic layers were dried (sodium sulfate) and concentrated. The remnant was triturated from methylene chloride, and the precipitate filtered and rinsed methylene chloride to give 0.23 g (82%) of the title compound as white powdery solid.


50 The solid was slurried in methanol and trifluoroacetic acid was added dropwise until all the material went into solution, the insoluble material was filtered away, and the mother liquor was concentrated *in vacuo* to yield 0.28 g (80%) of the TFA salt as a fluffy orange solid. ¹H NMR (300 MHz) δ 9.5 (m, 1H), 7.38 (m, 1H), 7.2-7.3 (m, 5H), 6.90 (d, J = 8.6 Hz, 2H), 6.76 (s, 1H), 6.51 (dd, J = 2.2, 8.2 Hz, 1H), 6.38 (d, J = 2.3 Hz, 1H), 4.44 (t, J = 4.9 Hz, 2H), 3.5-3.7 (m, 4H), 3.0-3.2 (m, 2H), 1.7-2.0 (m, 5H), 1.4-1.7 (m, 1H); IR (CHCl₃) 3271, 3022, 3009, 1670, 1610 cm⁻¹; MS (FD) m/e 457 (M⁺); HRMS (FAB) m/e calc'd for C₂₈H₂₈NO₃S (MH⁺): 458.1790. Found: 458.1781. Anal calc'd for C₂₈H₂₈NO₃S·CF₃COOH·1.2H₂O: C, 60.69, H, 5.12; N, 2.36. Found: C, 60.62, H, 4.82; N, 2.40

Preparation 18a2,8-Bis[(*tert*-butyldimethylsilyl)oxy]-5*H*-benzo[*b*]naphtho[2,1-*d*]pyran-5-one

5

10

15



20


A mixture of the product of Preparation 10 (7.0 g, 13.8 mmol) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (3.3 g, 14.5 mmol) in dichloroethane (100 mL) was heated at reflux overnight, inducing the formation of a precipitate. The mixture was filtered hot, rinsing the precipitate with methylene chloride, and the mother liquor concentrated *in vacuo*. The remnant was partitioned between hexane ether and water, and the organic layer was dried (magnesium sulfate), concentrated, and recrystallized from hexane to provide 5.5 g (79%) of the title product as a tan solid, mp 154–156°C. ¹H-NMR (300 MHz, CDCl₃) δ 9.69 (d, J = 9.4 Hz), 8.80 (s, 2H), 8.01 (d, J = 9.5 Hz), 7.34 (dd, J = 9.3, 2.5 Hz, 1H), 7.28 (d, J = 5.4 Hz, 1H), 6.90 (m, 2H), 1.05 (s, 9H), 1.03 (s, 9H), 0.29 (s, 12H); IR (CHCl₃) 1711, 1622, 1604 cm⁻¹; MS (FD) m/e 506 (M⁺); Anal. calc'd for C₂₉H₃₈O₄Si₂: C, 68.72; H, 7.57. Found: C, 68.93, H, 7.36.

25

Preparation 18b2,8-Bis[(*tert*-butyldimethylsilyl)oxy]-5*H*-benzo[*b*]naphtho[2,1-*d*]pyran-5-ol

30

35



40

45

By the procedure described for Preparation 4, the product of Preparation 18a (5.0 g, 9.9 mmol) was reacted with 1.0 M diisobutylaluminum hydride in toluene (11.9 mL, 11.9 mmol) to give, after recrystallization from hexane:ether, 4.14 g (82%) of the title compound as a white solid, mp 188–190°C. ¹H NMR (300 MHz, CDCl₃) δ 7.98 (d, J = 9.1 Hz, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.79 (d, J = 8.6 Hz, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.23 (d, J = 2.3 Hz, 1H), 7.18 (dd, J = 9.0, 2.4 Hz, 1H), 7.06 (d, J = 7.4 Hz, 1H), 6.67 (m 2H) 3.24 (d, J = 7.7 Hz, 1H), 1.04 (s, 9H), 1.02 (s, 9H), 0.27 (s, 6H), 0.27 (s, 6H); IR (CHCl₃) 3574 cm⁻¹; MS (FD) m/e 508 (M⁺); Anal. calc'd. for C₂₉H₄₀O₄Si₂: C, 68.44; H, 7.94. Found: C, 68.63; H, 8.11


50

55

Preparation 18c2,8-Bis[(tert-butyldimethylsilyl)oxy]-5-phenoxy-5*H*-benzo[*b*]naphtho[2,1-*d*]pyran

5

10




- 15 By the procedure described for Preparation 5, the product of Preparation 18b (3.5 g, 6.83 mmol) was reacted with phenol (3.2 g, 34.3 mmol) to give 3.82 g (95%) of the title compound as an amorphous white solid which was used without further purification. ¹H NMR (300 MHz) δ 7.9-8.1 (m, 4H), 7.61 (s, 1H), 7.3-7.5 (m, 3H), 7.2-7.3 (m, 3H), 7.11 (t, J = 7.3 Hz, 1H), 6.74 (dd, J = 8.5, 2.3 Hz, 1H), 6.62 (d, J = 2.4 Hz, 1H), 1.03 (s, 9H), 0.99 (s, 9H), 0.29 (s, 6H), 0.24 (s, 6H); ¹³C NMR (75 MHz) δ 157.9, 157.6, 154.3, 151.8, 135.1, 130.4, 130.1, 126.4, 125.8, 125.1, 124.9, 123.9, 123.6, 123.1, 121.1, 118.5, 116.7, 116.2, 115.7, 110.0, 94.8, 26.0, 25.9, 18.8, 18.7, -4.3, -4.4; MS (FD) m/e 584 (M+)

Preparation 18d2,8-Bis[(tert-butyldimethylsilyl)oxy]-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-5*H*-benzo[*b*]naphtho[2,1-*d*]pyran

25

30

35



- 40 By the procedure described for Preparation 6, the product of Preparation 18c (3.5 g, 6.0 mmol) was reacted with a 0.2 M THF solution of 4-[2-(1-piperidinyl)ethoxy]phenylmagnesium bromide to provide, after chromatography (silica gel, 3.2 hexane ethyl acetate, 0.1% ammonium hydroxide), 3.5 g (84%) of the title compound as a colorless gummy solid. ¹H NMR (300 MHz) δ 7.97 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 8.7 Hz, 1H), 7.76 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 2.4 Hz, 1H), 7.10 (m, 3H), 7.02 (s, 1H), 6.73 (d, J = 8.7 Hz, 2H), 6.53 (dd, J = 8.3, 2.4 Hz, 1H), 6.37 (d, J = 2.2 Hz, 1H), 3.95 (t, J = 6.0 Hz, 2H), 2.58 (t, J = 6.0 Hz, 2H), 2.38 (m, 4H), 1.4-1.5 (m, 4H), 1.3-1.4 (m, 2H), 1.00 (s, 9H), 0.94 (s, 9H), 0.25 (s, 6H), 0.19 (s, 6H); ¹³C NMR (75 MHz) δ 159.8, 157.6, 154.1, 154.0, 135.0, 132.2, 130.1, 128.6, 127.3, 126.3, 126.2, 125.6, 124.7, 123.4, 121.6, 118.0, 116.5, 115.0, 114.5, 110.3, 76.0, 66.8, 58.5, 55.6, 26.8, 26.0, 26.0, 25.0, 18.7, 18.7, -4.2, -4.3; MS (FD) m/e 696 (M+); Anal. calc'd. for C₄₂H₅₇NO₄Si₂: C, 72.46; H, 8.27; N, 2.01. Found: C, 72.53; H, 8.49; N, 2.08


50

55

Example 11b2,8-Dihydroxy-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-5*H*-benzo[*b*]naphtho[2,1-*d*]pyran

5

10



15

By the procedure described for Example 1, the product of Preparation 18d (3.4 g, 4.9 mmol) was reacted with a 1.0 M TBAF in THF (24.4 mmol) to provide, after chromatography (silica gel, 1:1 hexane ethyl acetate, 10% methanol, 0.1% ammonium hydroxide) and trituration with ether, 2.2 g (96%) of the title compound as a white solid, mp 158-161°C. ¹H NMR (300 MHz) δ 7.89 (d, J = 8.7 Hz, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.68 (m, 2H), 7.23 (d, J = 2.4 Hz, 1H), 7.09 (m, 3H), 6.97 (s, 1H), 6.71 (d, J = 8.7 Hz, 2H), 6.49 (dd, J = 8.3, 2.4 Hz, 1H), 6.36 (d, J = 2.3 Hz, 1H), 3.95 (l, J = 6.0 Hz, 2H), 2.60 (l, J = 6.0 Hz, 2H), 2.40 (m, 4H), 1.4-1.5 (m, 4H), 1.3-1.4 (m, 2H); ¹³C NMR (75 MHz) δ 159.5, 159.5, 155.8, 153.9, 135.0, 132.4, 130.1, 128.0, 126.7, 125.6, 125.4, 125.3, 124.7, 121.4, 119.9, 116.1, 114.8, 111.0, 110.1, 105.5, 75.8, 66.1, 58.3, 55.3, 26.3, 24.7; IR (KBr) 2934 cm⁻¹; MS (FD) m/e 468 (MH⁺); Anal. calc'd. for C₃₀H₂₉NO₄·H₂O: C, 74.19; H, 6.45; N, 2.88. Found: C, 74.13; H, 6.45; N, 2.88.

20


25

Preparation 22a2,8-Dimethoxy-5-[4-[(tert-butyldimethylsilyl)oxy]phenyl]-6*H*-benzo[c]phenanthrid-6-one

30

35

40



A mixture of the product of Preparation 22 (100 mg, 0.19 mmol) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (47 mg, 0.21 mmol) in dichloroethane (10 mL) was heated at reflux for 2 h, inducing the formation of a precipitate. The mixture was cooled to room temperature, filtered, and the filtrate diluted with CH₂Cl₂ (70 mL), washed with 1 N sodium hydroxide (2 x 70 mL), dried (Na₂SO₄) and concentrated to provide 98 mg (98%) of the title compound as a white, crystalline solid, mp 211-213°C. ¹H NMR (300 MHz, CDCl₃) δ 8.21 (d, J = 9.0 Hz, 1H), 8.16 (d, J = 8.9 Hz, 1H), 7.95 (d, J = 2.8 Hz, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.37 (dd, J = 9.0, 2.8 Hz, 1H), 7.25 (d, J = 9.7 Hz, 1H), 7.21 (d, J = 8.7 Hz, 2H), 7.08 (d, J = 2.7 Hz, 1H), 6.93 (d, J = 8.7 Hz, 2H), 6.66 (dd, J = 9.7, 2.8 Hz, 1H), 3.94 (s, 3H), 3.87 (s, 3H), 1.02 (s, 9H), 0.25 (s, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 163.1, 159.2, 156.9, 154.9, 137.3, 136.3, 133.8, 129.6, 128.3, 127.4, 126.4, 123.9, 123.7, 122.9, 120.7, 120.5, 119.5, 116.5, 115.7, 109.1, 106.9, 55.5, 55.1, 25.7, 18.3, -4.2; IR (CHCl₃) 1646, 1619 cm⁻¹; MS (FD) m/e 511 (M⁺); Anal. calc'd. for C₃₁H₃₃NO₄Si: C, 72.75; H, 6.51; N, 2.74. Found: C, 72.57; H, 6.50; N, 2.83.

55

Preparation 23a**2,8-Dimethoxy-5-(4-hydroxyphenyl)-6H-benzo[c]phenanthrid-6-one**

5

10

15

20

25

The product of Preparation 22a (6.8 g, 13.3 mmol) was dissolved in 1:1 acetonitrile methylene chloride (200 mL) and treated with hydrogen fluoride-pyridine (80 mL) for 1 h. The mixture was diluted with brine (500 mL) and extracted with THF (3 x 300 mL). The combined organic layers were neutralized with saturated sodium bicarbonate and the resulting aqueous layer was washed with THF (2 x 500 mL). All aqueous layers were then combined and washed with THF (500 mL), and the combined organic layers were dried (sodium sulfate), and concentrated, and the solid residue was washed with acetone to provide 5.27 g (100%) of the title compound as an off-white powder, mp 310°C. ¹H NMR (300 MHz, DMSO-d₆) δ 9.79 (bs, 1H), 8.52 (d, J = 9.0 Hz, 1H), 8.42 (d, J = 9.0 Hz, 1H), 7.72 (m, 2H), 7.47 (dd, J = 8.7, 2.3 Hz, 1H), 7.31 (d, 2.1 Hz, 1H), 7.21 (d, J = 9.6 Hz, 1H), 7.07 (d, J = 8.4 Hz, 2H), 6.82 (d, J = 8.3 Hz, 2H), 6.68 (dd, J = 9.3, 2.6 Hz, 1H), 3.87 (s, 3H), 3.79 (s, 3H); MS (FD) m/e 397 (M⁺).

Example 12a**2,8-Hydroxy-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-11,12-dihydro-6H-benzo[c]phenanthrid-6-one**

30

35

40

By the procedure described for Example 14, the product of Example 12 (310 mg, 0.61 mmol) was reacted with ethanethiol (189 mg, 3.1 mmol) and aluminum chloride (611 mg, 4.6 mmol) to provide after radial chromatography (silica gel, 1:1 hexane:ethyl acetate, 10-20% methanol, under an ammonia atmosphere) 237 mg (81%) of the title compound as a yellow foam which crystallized upon trituration with ether, mp 166-174°C. ¹H NMR (300 MHz, methanol-d₄) δ 7.80 (d, J = 8.9 Hz, 1H), 7.73 (d, J = 2.6 Hz, 1H), 7.30 (dd, J = 8.9, 2.7 Hz, 1H), 7.19 (d, J = 8.8 Hz, 2H), 6.97 (d, J = 8.9 Hz, 2H), 6.66 (d, J = 2.5 Hz, 1H), 6.56 (d, J = 8.7 Hz, 1H), 6.21 (dd, J = 8.7, 2.6 Hz, 1H), 4.16 (t, J = 5.6 Hz, 2H), 2.86 (s, 4H), 2.81 (t, J = 5.6 Hz, 2H), 2.59 (m, 4H), 1.6-1.7 (m, 4H), 1.4-1.6 (m, 2H); IR (CHCl₃) 3673, 1637, 1602 cm⁻¹; MS (FD) m/e 482 (M⁺), Anal. calc'd for C₃₀H₃₀N₂O₄·H₂O: C, 71.96; H, 6.4%; N, 5.60. Found: C, 71.68, H, 6.63, N, 5.46.

50

55


Example 12b

2,8-Dimethoxy-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-11,12-dihydro-6H-benzo[c]phenanthridine

5

10

15



A solution of the product of Example 12 (350 mg, 0.69 mmol) in THF (25 mL) was treated with lithium aluminum hydride (129 mg, 3.4 mmol) inducing a moderate exotherm. The mixture was allowed to return to room temperature and stirred for 2 h, then briefly warmed to reflux, cooled, and quenched with ethyl acetate (50 mL) followed by saturated ammonium chloride (50 mL). The aqueous layer was extracted with ethyl acetate (2 x 50 mL), and the combined organic layers were dried (sodium sulfate), concentrated, and purified via radial chromatography (silica gel, 1:1 hexane:ethyl acetate, 5% methanol, under an ammonia atmosphere) to provide 248 mg (64%) of the title compound as a yellow foam: ¹H NMR (300 MHz, CDCl₃) δ 7.28 (d, J = 8.5 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.79 (m, 3H), 6.72 (d, J = 2.6 Hz, 1H), 6.65 (d, J = 9.0 Hz, 2H), 6.58 (d, J = 2.6 Hz, 1H), 6.52 (dd, J = 8.6, 2.6 Hz, 1H), 4.65 (s, 2H), 3.94 (t, J = 6.1 Hz, 2H), 3.74 (s, 3H), 3.74 (s, 3H), 2.96 (dd, J = 8.3, 5.6 Hz, 2H), 2.81 (dd, J = 8.3, 5.9 Hz, 2H), 2.66 (t, J = 6.1 Hz, 2H), 2.43 (m, 4H), 1.5-1.6 (m, 4H), 1.3-1.5 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 158.5, 158.3, 153.3, 141.7, 138.4, 134.6, 132.3, 126.6, 126.2, 125.3, 122.9, 121.7, 120.5, 114.9, 113.4, 112.3, 111.2, 111.0, 65.8, 57.8, 55.6, 55.2, 55.1, 54.8, 29.0, 25.7, 24.0, 22.2; IR (CHCl₃) 1610, 1506 cm⁻¹; MS (FD) m/e 496 (M⁺); Anal. calc'd for C₃₂H₃₆N₂O₃: C, 77.37; H, 7.32; N, 5.64. Found: C, 77.25; H, 7.12; N, 5.75.

30


Example 12c

2,8-Dimethoxy-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6H-benzo[c]phenanthrid-6-one

35

40

45




By the method described for Example 12, the product of Preparation 23a (4.8 g, 12.1 mmol), triphenylphosphine (6.3 g, 24.2 mmol), and 1-(2-hydroxyethyl)piperidine (3.9 g, 30.3 mmol) were reacted with diethyl diazodicarboxylate (DEAD) (4.2 g, 24.2 mmol) to provide, after chromatography (silica gel, 1:1 hexane:ethyl acetate, 5-20% methanol, 0.1% ammonium hydroxide) and recrystallization from ethyl acetate, 5.14 g (84%) of the title compound as a fluffy white solid, mp 176°C. ¹H NMR (300 MHz, CDCl₃) δ 8.25 (d, J = 9.1 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 7.96 (d, J = 2.8 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.40 (dd, J = 9.0, 2.8 Hz, 1H), 7.31 (d, J = 9.7 Hz, 1H), 7.26 (d, J = 8.8 Hz, 2H), 7.10 (d, J = 2.7 Hz, 1H), 6.99 (d, J = 8.9 Hz, 2H), 6.70 (dd, J = 9.6, 2.7 Hz, 1H), 4.16 (t, J = 6.0 Hz, 2H), 3.95 (s, 3H), 3.88 (s, 3H), 2.81 (t, J = 6.0 Hz, 2H), 2.53 (m, 4H), 1.5-1.7 (m, 4H), 1.4-1.5 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 163.2, 159.2, 157.9, 156.9, 136.3, 135.7, 133.7, 129.7, 128.3, 127.3, 126.4, 123.9, 123.7, 122.8, 120.5, 119.4, 116.6, 115.7, 115.1, 109.1, 106.9, 66.2, 57.8, 55.5, 55.1, 55.0, 25.9, 24.1; IR (CHCl₃) 1647, 1619 cm⁻¹; MS (FD) m/e 508 (M⁺); Anal. calc'd. for C₃₂H₃₂N₂O₄: C, 75.56; H, 6.35; N, 5.51. Found: C, 75.58, H, 6.28, N, 5.77.

Example 12d**2,8-Hydroxy-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6H-benzo[c]phenanthrid-6-one**

5

10

15



20


25

By the procedure described for Example 14, the product of Example 12a (500 mg, 0.98 mmol) was reacted with ethanethiol (304 mg, 4.9 mmol) and aluminum chloride (987 mg, 7.4 mmol) to provide after chromatography (silica gel, 1.1 hexane ethyl acetate, 10-30% methanol, 0.1% ammonium hydroxide) and crystallization from methanol 397 mg (84%) of the title compound as a white powder. An analytical sample was recrystallized from methanol/CHCl₃, mp 227-232°C. ¹H NMR (300 MHz, DMSO-d₆) δ 10.15 (bs, 1H), 9.82 (bs, 1H), 8.43 (d, J = 8.9 Hz, 1H), 8.34 (d, J = 9.2 Hz, 1H), 7.69 (s, 1H), 7.63 (d, J = 9.0 Hz, 1H), 7.34 (d, J = 8.9 Hz, 1H), 7.0-7.3 (m, 6H), 6.58 (d, J = 9.6 Hz, 1H), 4.13 (t, J = 5.6 Hz, 2H), 2.69 (t, J = 5.5 Hz, 2H), 2.46 (m, 4H), 1.3-1.6 (m, 6H); ¹³C NMR (75 MHz, DMF-d₇/acetone-d₆/CDCl₃) δ 162.2, 158.4, 157.3, 155.9, 137.4, 137.2, 133.9, 130.8, 127.6, 127.5, 126.9, 125.0, 124.0, 123.1, 121.1, 119.0, 117.3, 115.7, 115.5, 112.8, 110.6, 63.4, 55.8, 53.6, 23.2, 22.1, IR (KBr) 3303, 1643, 1602 cm⁻¹; MS (FD) m/e 480 (M⁺), Anal. calc'd. for C₃₀H₂₈N₂O₄·0.5H₂O. C, 73.59; H, 5.98; N, 5.72. Found: C, 73.72; H, 5.88; N, 5.71.

Example 13**2,8-Dimethoxy-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6H-benzo[c]phenanthridine**

30

40



55

A solution of the product of Example 12a (3.82 g, 7.51 mmol) in THF (250 mL) was treated with lithium aluminum hydride (1.43 g, 37.5 mmol) resulting in a moderate exotherm. After the exotherm ceased, the mixture was warmed to reflux overnight, cooled to room temperature, and quenched cautiously with ethyl acetate (200 mL) followed by 1 N sodium hydroxide (200 mL). The layers were separated and the aqueous layer extracted with ethyl acetate (2 x 200 mL) and the combined organic layers were washed with brine (200 mL), dried (sodium sulfate), and concentrated. The residue was recrystallized from hexane ethyl acetate to provide 3.24 g (87%) of the title compound as an off-white solid, mp 136-137 °C. ¹H NMR (300 MHz, CDCl₃) δ 7.91 (d, J = 8.6 Hz, 1H), 7.74 (d, J = 8.8 Hz, 2H), 7.61 (d, J = 8.6 Hz, 1H), 7.12 (d, J = 2.5 Hz, 1H), 6.95 (dd, J = 9.2, 2.6, 1H), 6.91 (dd, J = 8.5, 2.6 Hz, 1H), 6.6-6.8 (m, 5H), 4.75 (s, 2H), 3.95 (t, J = 6.1 Hz, 2H), 3.90 (s, 3H), 3.79 (s, 3H), 2.68 (t, J = 6.1 Hz, 2H), 2.44 (m, 4H), 1.5-1.7 (m, 4H), 1.4-1.5 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 159.1, 157.3, 153.4, 143.5, 137.9, 135.0, 134.1, 126.5, 125.6, 124.9, 124.2, 123.8, 123.7, 122.4, 121.7, 118.1, 114.9, 113.8, 111.2, 106.4, 65.8, 57.8, 55.8, 55.2, 54.8, 25.7, 24.0, IR (CHCl₃) 1506 cm⁻¹; MS (FD) m/e 494 (M⁺), Anal. calc'd. for C₃₂H₃₄N₂O₃. C, 77.70; H, 6.94; N, 5.66. Found: C, 77.54; H, 6.99; N, 5.63.


Preparation 11

3,9-Bis[(*tert*-butylidimethylsilyl)oxy]-6-[4-(2-diethylaminoethoxy)phenyl]-6-*H*[1]benzothieno[3,2 -c] [1]benzopyran

5

10

15



20 By the method described in Preparation 8, the product of Preparation 7 (500 mg, 0.85 mmol), triphenylphosphine (892 mg, 3.4 mmol), and *N,N*-diethylethanamine (496 mg, 438 mL, 4.23 mmol) were reacted with diethyl azodicarboxylate (DEAD) (592 mg, 535 mL, 3.4 mmol) in toluene (35 mL). Chromatography (silica gel, 3:1 hexane:ethyl acetate, 0.1% ammonium hydroxide) provided 540 mg (92%) of the title compound as a colorless oil: ¹H NMR (300 MHz) δ 7.46 (d, J = 2.5 Hz, 1H), 7.3-7.4 (m, 4H), 6.86 (m, 3H), 6.69 (s, 1H), 6.51 (dd, J = 8.3, 2.3 Hz, 1H), 6.37 (d, 2.2 Hz, 1H), 3.98 (t, J = 6.3 Hz, 2H), 2.77 (t, J = 6.3 Hz, 2H), 2.54 (q, J = 7.1 Hz, 4H), 0.99 (s, 9H), 0.97 (t, J = 7.0 Hz, 6H), 0.96 (s, 9H), 0.22 (s, 6H), 0.21 (s, 6H); ¹³C NMR (125 MHz) δ 160.0, 157.5, 153.7, 153.3, 140.8, 132.6, 132.3, 131.1, 129.7, 125.7, 124.6, 122.5, 119.2, 115.0, 114.2, 113.9, 113.7, 109.3, 78.1, 67.2, 52.3, 48.1, 26.0, 26.0, 18.6, 12.5, -4.3; MS (FD+) m/e 689 (M+);

25


Preparation 12

3,9-Bis[(*tert*-butylidimethylsilyl)oxy]-6-[4-[2-(1-morpholinyl)ethoxy]phenyl]-6-*H*[1]benzothieno[3,2 -c] [1]benzopyran

30

40


45



50 By the method described in Preparation 8, the product of Preparation 7 (500 mg, 0.85 mmol), triphenylphosphine (892 mg, 3.4 mmol), and 1-(2-hydroxyethyl)morpholine (555 mg, 512 mL, 4.23 mmol) were reacted with diethyl azodicarboxylate (DEAD) (592 mg, 535 mL, 3.4 mmol) in toluene (35 mL). Chromatography (silica gel, 3:1 hexane:ethyl acetate, 0.1% ammonium hydroxide) provided 569 mg (95%) of the title compound as a pink foam: ¹H NMR (300 MHz) δ 7.46 (d, J = 2.1 Hz, 1H), 7.2-7.3 (m, 4H), 6.86 (m, 3H), 6.70 (s, 1H), 6.51 (dd, J = 8.2, 2.3 Hz, 1H), 6.37 (d, 2.7 Hz, 1H), 4.04 (t, J = 5.8 Hz, 2H), 3.57 (t, J = 4.5 Hz, 2H), 2.69 (t, J = 5.7 Hz, 2H), 2.47 (m, 4H), 0.99 (s, 9H), 0.96 (s, 9H), 0.22 (s, 6H), 0.21 (s, 6H); ¹³C NMR (125 MHz) δ 159.8, 157.6, 153.7, 153.2, 140.8, 132.5, 132.5, 131.1, 129.7, 125.8, 124.6, 122.5, 119.2, 115.1, 114.2, 114.0, 113.8, 109.3, 78.2, 67.0, 66.2, 57.9, 54.6, 26.0, 25.9, 18.6, -4.3; MS (FD+) m/e 703 (M+);

Preparation 13**3,9-Bis[(*tert*-butyldimethylsilyl)oxy]-6-*H*-benzofuro[3,2-*c*] [1]benzopyran-6-one**

5




Coumestrol (10 g 37.3 mmol) was slurried in methylene chloride (600 mL), cooled to 0°C, and treated with triethylamine (24.9 g, 34.3 mL, 246 mmol) and *tert*-butyldimethylsilyl chloride (24.7 g, 164 mmol). The mixture was warmed to ambient temperature and stirred overnight, during which it slowly became homogeneous. After dilution with ether (800 mL), the mixture was washed with brine (800 mL) and the aqueous layer was extracted with ether (500 mL). The combined organic layers were dried (sodium sulfate), concentrated, and the residue recrystallized from hexane to provide 14.2 g (77%) of the title compound as a white powder, mp 118–119°C. ¹H-NMR (300 MHz, CDCl₃) δ 7.90 (d, J = 8.5 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.10 (d, J = 2.0 Hz, 1H), 6.97 (m, 2H), 6.90 (dd, J = 8.5, 2.0 Hz, 1H), 1.03 (s, 9H), 1.02 (s, 9H), 0.28 (s, 6H), 0.25 (s, 6H); IR (CHCl₃) 1733 cm⁻¹, MS (FD+) m/e 496 (M+), Anal. calc'd. for C₂₇H₃₆O₅Si₂: C, 65.27; H, 7.32. Found: C, 65.57, H, 7.26.

Preparation 14**3,9-Bis[(*tert*-butyldimethylsilyl)oxy]-6-*H*-benzofuro[3,2-*c*] [1]benzopyran-6-ol**

35

40



By the method described in Preparation 4, the product of Preparation 13 (5.0 g, 10.0 mmol) was reacted with a 1.0 M toluene solution of diisobutylaluminum hydride (12.0 mL, 12.0 mmol) in toluene (450 mL). Recrystallization from hexane gave 1.26 g of the title compound as mixture with its aldehyde tautomer. Chromatography (silica gel, 2–15% ethyl acetate/hexane) of the mother liquor provided 1.37 g of starting material (approximately 67% pure) and, after recrystallization, 580 mg of title compound for a total output of 1.85 g (37%) of the tautomeric mixture: ¹H NMR (300 MHz) δ 10.15 (s, 0.5H), 9.2 (br s, 0.5H), 7.99 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.50 (m, 0.5H), 7.09 (d, J = 2.0 Hz, 1H), 6.96 (m, 1H), 6.6–6.7 (m, 2H), 6.55 (m, 0.5H), 1.01 (s, 9H), 1.00 (s, 9H), 0.27 (s, 6H), 0.25 (s, 6H), IR (CHCl₃) 3550, 1663 cm⁻¹; MS (FD) m/e 499 (M⁺), Anal. calc'd. for C₂₇H₃₈O₅Si₂: C, 65.02; H, 7.69. Found C, 65.32; H, 7.76


55

Preparation 153,9-Bis[(*tert*-butyldimethylsilyl)oxy]-6-phenoxy-6-*H*-benzofuro[3,2-c][1]benzopyran

5

10

15



By the method described in Preparation 5, the product of Preparation 14 (464 mg, 0.93 mmol) was reacted with phenol (1.05 g, 11.2 mmol) in chlorobenzene (25 mL) containing anhydrous magnesium sulfate (1.0 g) to yield 467 mg (87%) of the crude title compound as an unstable pink foam which was used without purification: ^1H NMR (300 MHz) δ 7.1-7.7 (m, 8H), 6.6-6.9 (m, 3H), 1.01 (s, 9H), 1.00 (s, 9H), 0.28 (s, 6H), 0.25 (s, 6H).


20

Preparation 163,9-Bis[(*tert*-butyldimethylsilyl)oxy]-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-*H*-benzofuro[3,2-c][1]benzopyran

25

30

35



- 40 By the method described in Preparation 6, the product of Preparation 15 (467 mg, 0.81 mmol) was reacted with a 0.5 MTHF solution of 4-[2-(1-piperidinyl)ethoxy]phenylmagnesium bromide (2.6 mL, 1.62 mmol) in toluene (15 mL). Radial chromatography (silica gel, 2:1 hexane:ethyl acetate, 1% methanol under an ammonia atmosphere) provided 500 mg (90%) of the title compound as a colorless, gummy solid. ^1H NMR (300 MHz) δ 7.39 (m, 3H), 7.04 (d, $J = 2.0$ Hz, 1H), 6.92 (d, $J = 8.6$ Hz, 2H), 6.78 (d, $J = 8.4$ Hz, 1H), 6.68 (d, $J = 8.1$ Hz, 1H), 6.68 (s, 1H), 6.53 (dd, $J = 8.2, 2.2$ Hz, 1H), 6.38 (d, $J = 2.6$ Hz, 1H), 4.05 (t, $J = 5.9$ Hz, 2H), 2.64 (t, $J = 6.1$ Hz, 2H), 2.42 (m, 4H), 1.4-1.6 (m, 4H), 1.3-1.4 (m, 2H), 0.96 (s, 9H), 0.95 (s, 9H), 0.20 (s, 6H), 0.19 (s, 6H). ^{13}C NMR (125 MHz) δ 160.3, 158.0, 156.8, 155.5, 154.0, 148.2, 132.7, 129.8, 121.6, 121.1, 119.8, 117.3, 115.3, 113.8, 110.6, 109.8, 109.1, 103.8, 79.0, 66.9, 58.5, 55.6, 26.8, 26.0, 26.0. MS (FD) m/e 686 (M+). Anal. calc'd. for $C_{40}H_{55}NO_5Si_2$: C, 70.03; H, 8.08; N, 2.04. Found: C, 70.28; H, 8.14; N, 2.08.

45

50

55


Example 11

3,9-Dihydroxy-6-[4-(1-piperidinyl)ethoxy]phenyl]-6-H-benzofuro[3,2-c] [1]benzopyran

5

10

15




By the procedure described for Example 1, the product of Preparation 16 (520 mg, 0.76 mmol) was reacted with 1.0 M TBAF in THF (4.5 mmol) to give, after radial chromatography (silica gel, 1.1 hexane:ethyl acetate, 10% methanol, under an ammonia atmosphere) 292 mg (72%) of the title compound as a bright red foam, which crystallized from carbon tetrachloride. ¹H NMR (300 MHz, dimethylformamide-*d*₇) δ 10.00 (br s, 1H), 9.83 (br s, 1H), 7.3-7.5 (m, 3H), 7.10 (s, 1H), 6.96 (d, J = 8.5 Hz, 2H), 6.7-6.9 (m, 3H), 6.54 (dd, J = 8.1, 1.8 Hz, 1H), 6.42 (s, 1H), 4.10 (t, J = 5.8 Hz, 2H), 2.67 (m, 2H), 2.44 (m, 4H), 1.4-1.6 (m, 4H), 1.3-1.4 (m, 2H); ¹³C NMR (125 MHz, dimethylformamide-*d*₇) δ 160.2, 159.9, 156.8, 156.4, 155.1, 147.2, 133.0, 129.5, 121.4, 119.5, 118.9, 115.1, 112.9, 109.2, 108.9, 108.3, 104.3, 98.7, 78.5, 66.5, 58.2, 55.3, 26.4, 24.6; IR (KBr) 3220 cm⁻¹; HRMS (FAB+) m/e calc'd for C₂₈H₂₈NO₅ 458 1967 (MH⁺), found 458 1974; Anal. calc'd. for C₂₈H₂₇NO₄S·0.25CCl₄: C, 68.40, H, 5.49, N, 2.82. Found: C, 68.58; H, 5.81, N, 2.94.

Preparation 17

30 2-Methoxy-8-hydroxy-11,12-dihydro-5H-benzo[b]naphtho[2,1-d]pyran-5-one

35

40



To a solution of 1-carbomethoxy-6-methoxy-2-tetralone (see, Colvin, Martin, and Shroot, Chemistry and Industry, 2130 (1966)) (18.0 g, 76.8 mmol) and resorcinol (8.9 g, 80.7 mmol) stirring at ambient temperature in toluene (450 mL) was added phosphorus oxychloride (12.0 g, 7.3 mL, 18.3 mmol) dropwise, and the mixture warmed to 80°C for 12 h. After cooling to room temperature, the mixture was poured into water (500 mL) and filtered, rinsing the precipitate with ether. The filtrate layers were separated, the aqueous layer was extracted with ethyl acetate (3 x 500 mL), and the combined organic layers were dried (sodium sulfate) and concentrated. Recrystallization of the residue from methanol provided 16.0 g of the title compound as a yellow solid, mp 244-249°C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 10.55 (br s, 1H), 8.24 (d, J = 8.6 Hz, 1H), 7.75 (d, J = 8.7 Hz, 1H), 6.6-7.0 (m, 4H), 3.76 (s, 3H), 2.8-3.0 (m, 4H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 170.3, 160.3, 158.3, 158.1, 153.3, 147.7, 137.5, 127.4, 125.8, 122.5, 114.5, 112.6, 112.4, 110.9, 101.4, 54.6, 26.3, 22.7; IR (KBr) 3250, 1676, 1618 cm⁻¹; MS (FD+) m/e 294 (M⁺); Anal. calc'd. for C₁₈H₁₄O₄: C, 73.45, H, 4.80. Found: C, 73.15, H, 4.86.


55

Preparation 18**2,8-Bis[(*tert*-butyldimethylsilyl)oxy]-11,12-dihydro-5*H*-benzo[*b*]naphtho[2,1-*d*]pyran-5-one**

5

10

15



20


By the procedure described in Preparation 3, the product of Preparation 17 (4.17 g, 14.2 mmol) was reacted with ethanethiol (3.53 g, 3.95 mL, 56.8 mmol) and aluminum chloride (9.0 g, 67.5 mmol) in methylene chloride (100 mL). The crude product was further reacted with triethylamine (8.6 g, 11.9 mL, 85.2 mmol) and *tert*-butyldimethylsilyl chloride (8.6 g, 56.8 mmol) in methylene chloride (100 mL) to provide, after recrystallization from hexane, the title product as a yellow solid, mp 145-147°C. ¹H NMR (300 MHz, CDCl₃) δ 8.37 (d, J = 8.6 Hz, 1H), 7.58 (d, J = 9.3 Hz, 1H), 6.83 (s, 1H), 6.81 (m, 2H), 6.72 (d, J = 2.4 Hz, 1H), 2.8-3.0 (m, 4H), 1.00 (s, 18H), 0.27 (s, 6H), 0.24 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 159.8, 158.6, 155.4, 153.9, 147.1, 137.7, 128.6, 125.0, 123.9, 119.0, 118.1, 117.5, 117.3, 113.8, 107.5, 27.4, 25.7, 25.6, 23.9, 18.3, 18.2, -4.3, -4.4; IR (CHCl₃) 1708, 1612 cm⁻¹; MS (FD) m/e 508 (M+).

25

Preparation 19**6-Methoxy-1-[(4-hydroxy)phenyl]imino-1,2,3,4-tetrahydronaphthalene**

30

35



40

A mixture of 6-methoxyletralone (25 g, 142 mmol) and 4-hydroxyaniline (16.3 g, 149 mmol) was heated to 180°C under a nitrogen stream for 2 h. After cooling to ambient temperature, the solid mass was recrystallized from toluene/methanol: ¹H NMR (300 MHz) δ 8.15 (d, J = 9.7 Hz, 1H), 6.5-7.9 (m, 6H), 3.80 (s, 3H), 2.84 (t, J = 7.3 Hz, 2H), 2.51 (t, J = 6.8 Hz, 2H), 1.85 (m, 2H).


45

50

55

Preparation 20**6-Methoxy-1-[(4-hydroxy)phenyl]imino-1,2,3,4-tetrahydronaphthalene**

5




The product of Preparation 19 (36 g, 134.7 mmol) was dissolved in 1.1 methylene chloride. THF (300 mL) and treated with triethylamine (28.6 g, 39.4 mL, 283 mmol) and *tert*-butyldimethylsilyl chloride (30.5 g, 202 mmol). The mixture was stirred overnight and additional portions of triethylamine (6.8 g, 9.4 mL, 67 mmol) and *tert*-butyldimethylsilyl chloride (10.2 g, 67 mmol) were added to drive the reaction to completion. After 5 h, the mixture was diluted with ether (500 mL), filtered, concentrated, and the residue washed with hexane/ether. The extracts were filtered, concentrated and the residue purified by rapid chromatography (silica gel, 18:1-10:1 hexane ethylacetate) to give 21.0 g (41%) of the title compound as light yellow foam: ^1H NMR (300 MHz, CDCl_3) δ 8.32 (d, $J = 9.7$ Hz, 1H), 6.86 (m, 3H), 6.73 (m, 3H), 3.92 (t, $J = 5.8$ Hz, 2H), 2.57 (t, $J = 6.8$ Hz, 2H), 1.96 (m, 2H), 1.05 (s, 9H), 0.26 (s, 6H).

Preparation 21**6-Methoxy-1-[*N*-[[4-(*tert*-butyldimethylsilyl)oxy]phenyl]-*N*-(2,5-dimethoxybenzoyl)]amino-3,4-dihydronaphthalene**

35

40



The product of Preparation 20 (10.2 g, 26.8 mmol) was dissolved in methylene chloride (100 mL), cooled to 0°C and treated with triethylamine (3.8 g, 5.2 mL, 37.5 mmol) followed by a solution of 2,5-dimethoxybenzoylchloride (6.72 g, 33.5 mmol) in dichloromethane (25 mL). The mixture was warmed to reflux overnight, then treated with additional triethylamine (1.4 g, 1.9 mL, 13.4 mmol) and acid chloride (2.7 g, 13.4 mmol) and heating continued for an additional 12 h. After concentration *in vacuo*, the residue was dissolved in ether (250 mL), washed with brine (250 mL), dried (sodium sulfate), and concentrated. Purification of the residue by chromatography (silica gel, 9:1-4:1 hexane ethyl acetate) provided 10.3 g of the title compound as a white foam: ^1H NMR (300 MHz, CDCl_3) δ 6.4-7.6 (br m, 11H), 5.83 (br s, 1H), 3.4-3.8 (br m, 9H), 1.9-3.0 (br m, 4H), 0.95 (2 br s, 9H), 0.14 (2 br s, 6H). IR (CHCl_3) 1651, 1607, 1507 cm^{-1} ; MS (FD) m/e 545 (M+); Anal calc'd for $\text{C}_{32}\text{H}_{39}\text{NO}_5\text{Si}$: C, 70.43, H, 7.20, N, 2.57. Found C, 70.53, H, 7.26; N, 2.76.


55

Preparation 222,8-Dimethoxy-5-[4-[(*tert*-butyldimethylsilyl)oxy]phenyl]-11,12-dihydro-6*H*-benzo[c]phenanthrid-6-one

5

10

15



A solution of the product of Preparation 21 (2.73 g, 5 mmol) in benzene (250 mL) was degassed via 3 freeze/pump/thaw cycles and irradiated with a 450 Watt internal mercury lamp in a quartz immersion well under nitrogen. After 22 h, the mixture was concentrated and the residue purified by chromatography (silica gel, 20:1 toluene:ether) to provide 675 mg (26%) of the title compound as a yellow foam. An analytical sample was obtained by crystallization from hexane/ether as light yellow crystals, mp 194–95°C. ¹H NMR (300 MHz, CDCl₃) δ 7.94 (d, J = 2.8 Hz, 1H), 7.73 (d, J = 8.9 Hz, 1H), 7.32 (dd, J = 8.9, 2.8 Hz, 1H), 7.17 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 6.76 (d, J = 2.6 Hz, 1H), 6.67 (d, J = 8.8 Hz, 1H), 6.35 (dd, J = 8.8, 2.7 Hz, 1H), 3.94 (s, 3H), 3.75 (s, 3H), 2.90 (s, 4H), 0.99 (s, 9H), 0.21 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 162.6, 158.3, 157.7, 154.4, 139.7, 134.3, 133.6, 129.9, 129.8, 128.1, 126.2, 123.7, 123.2, 122.6, 119.8, 114.9, 112.7, 110.4, 108.6, 55.3, 54.8, 29.3, 25.5, 23.5, 18.1.

IR (CHCl₃) 1640, 1615, 1507 cm⁻¹, MS (FD+) m/e 513 (M⁺), Anal. calc'd for C₃₁H₃₅NO₄Si: C, 72.48; H, 6.87; N, 2.73. Found: C, 72.66; H, 6.95; N, 2.86


30

Preparation 23

35

2,8-Dimethoxy-5-(4-hydroxyphenyl)-11,12-dihydro-6*H*-benzo[c]phenanthrid-6-one

40



The product of Preparation 22 (790 mg, 1.5 mmol) was dissolved in 3:2 acetonitrile:methylene chloride (50 mL) and treated with hydrogen fluoride-pyridine (10 mL) in 2 portions at 1 h intervals. After further stirring for 1 h, the mixture was diluted with THF (100 mL) and filtered, washing with methanol and ether. The filtrates were diluted with THF (200 mL) and washed with brine (200 mL) and saturated sodium bicarbonate (200 mL). The combined aqueous layers were extracted with THF (100 mL) and the combined organic layers were dried (sodium sulfate) and concentrated to provide 340 mg (57%) of a yellow powder, mp 250–275°C, which was used without purification: ¹H NMR (300 MHz, dimethylformamide-*d*₇) δ 9.80 (br s, 1H), 7.91 (d, J = 9.7 Hz, 1H), 7.81 (d, J = 1.9 Hz, 1H), 7.44 (dd, J = 9.7, 1.9 Hz, 1H), 7.20 (d, J = 8.7 Hz, 2H), 6.8–7.0 (m, 4H), 6.47 (dd, J = 8.7, 1.9 Hz, 1H), 3.94 (s, 3H), 3.74 (s, 3H), 2.89 (m, 4H); MS (FD+) m/e 399 (M⁺)

55

Example 12

2,8-Dimethoxy-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]11,12-dihydro-6H-benzo[c]phenanthrid-6-one

5

10

15

20

To a solution of the product of Preparation 23 (340 mg, 0.85 mmol), triphenylphosphine (446 mg, 1.7 mmol), and 1-(2-hydroxyethyl)piperidine (275 mg, 2.1 mmol) in THF (20 mL) was added diethyl azodicarboxylate (DEAD) (296 mg, 268 mL, 1.7 mmol) and the mixture was stirred at ambient temperature overnight. After concentration *in vacuo*, chromatography (silica gel, 1:1 hexane:ethyl acetate, 5-20% methanol, 0.1% ammonium hydroxide) provided 338 mg (66%) of the title compound as a yellow foam. ¹H NMR (300 MHz) δ 7.82 (m, 2H), 7.35 (dd, J = 9.7, 2.9 Hz, 1H), 7.23 (d, J = 9.7 Hz, 2H), 6.91 (d, J = 9.7 Hz, 2H), 6.82 (m, 1H), 6.70 (d, J = 9.7 Hz, 1H), 6.38 (dd, J = 9.7, 1.9 Hz, 1H), 4.12 (t, J = 5.8 Hz, 2H), 3.90 (s, 3H), 3.70 (s, 3H), 2.86 (m, 6H), 2.65 (m, 4H), 1.5-1.7 (m, 4H), 1.4-1.5 (m, 2H).

25

Example 13
2,8-Dimethoxy-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6H-benzo[c]phenanthridine

30

35

40

45

A solution of the product of Example 12 (753 mg, 1.47 mmol) was dissolved in dichloroethane (20 mL), treated with DDQ (352 mg, 1.55 mmol), and warmed to 80°C. After several hours, the mixture was cooled to ambient temperature, diluted with methylene chloride (100 mL), washed with saturated sodium carbonate, and the organic layer dried (sodium sulfate) and concentrated. The residue was purified via chromatography (silica gel, 1:1 hexane:ethyl acetate, 15% methanol) to give 330 mg (44%) of a yellow solid.


The solid obtained above (309 mg, 0.61 mmol) was dissolved in THF (25 mL) and treated with lithium aluminum hydride (LAH) (115 mg, 3.05 mmol) at ambient temperature. After 10 min, excess LAH was quenched with ethyl acetate (50 mL) and the mixture was washed with saturated ammonium chloride (25 mL). The aqueous layer was washed with ethyl acetate (25 mL) and the combined organic layers were washed with brine (25 mL), dried (sodium sulfate), concentrated, and subjected to radial chromatography (silica gel, 1:1 hexane ethyl acetate, 5% methanol, under an ammonia atmosphere). The product was then dissolved in glacial acetic acid (10 mL) and treated with sodium borohydride (69 mg, 1.82 mmol). After 1 h, the mixture was quenched with saturated sodium bicarbonate and partitioned between methylene chloride and saturated sodium bicarbonate. The organic layer was dried (sodium sulfate), concentrated, and the residue used without further purification: ¹H NMR (300 MHz) δ 7.99 (d, J = 8.6 Hz, 1H), 7.82 (d, J = 8.6 Hz, 1H), 7.74 (d, J = 9.4 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.28 (d, J = 2.3 Hz, 1H), 6.92 (m, 2H), 6.81 (d, J = 2.3 Hz, 1H), 6.69 (d, J = 9.2 Hz, 2H), 6.63 (d, J = 9.1, 2H), 3.89 (t, J = 6.2 Hz, 2H), 3.87 (s, 3H), 3.75 (s, 3H), 2.57 (t, J = 6.1 Hz, 2H), 2.39 (m, 4H), 1.4-1.5 (m, 4H), 1.3-1.4 (m, 2H)

Example 14**2,8-Dihydroxy-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6H-benzo[c]phenanthridine**

5

10

15



A solution of the product of Example 13 (195 mg, 0.39 mmol) in methylene chloride (25 mL) was treated with ethanethiol (200 mg, 220 mL, 3.2 mmol) and aluminum chloride (320 mg, 2.4 mmol). After stirring for 4 h at ambient temperature, the mixture was quenched carefully with THF (25 mL) and saturated sodium bicarbonate (25 mL). The layers were separated, the aqueous layer was extracted with THF (25 mL), and the combined organic layers were dried (sodium sulfate) and concentrated. The residue was purified by radial chromatography (silica gel, 1:1 hexane:ethyl acetate, 10-20% methanol, under an ammonia atmosphere) to provide 110 mg (60%) of the title compound as a tan foam. An analytical sample was crystallized from methanol as a light red solid: ¹H NMR (300 MHz dimethylformamide-*d*₇) δ 9.92 (br s, 1H), 9.74 (br s, 1H), 7.99 (d, J = 8.8 Hz, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.69 (d, J = 9.0 Hz, 1H), 7.63 (d, J = 8.7 Hz, 1H), 7.23 (d, J = 2.0 Hz, 1H), 6.96 (dd, J = 9.0, 2.1 Hz, 1H), 6.84 (dd, J = 8.4, 2.1 Hz, 1H), 6.73 (m, 5H); 3.92 (t, J = 5.9 Hz, 2H), 2.57 (t, J = 5.9 Hz, 2H), 2.38 (m, 4H), 1.4-1.5 (m, 4H), 1.3-1.4 (m, 2H); IR (KBr) 3560, 3490 cm⁻¹; MS (FD+) m/e 466 (M⁺); Anal. calc'd. for C₃₀H₃₀N₂O₃·0.5H₂O: C, 75.75; H, 6.58. N, 5.89. Found: C, 75.82; H, 6.76, N, 5.95.


30

Example 15**2,8-dihydroxy-5-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-5H-benzo[b]naphtho[2,1-*a*]pyran**

This compound is prepared in accordance with the foregoing teaching and examples.

35

40



In the examples illustrating the methods, a post-menopausal model was used in which effects of different treatments upon circulating lipids were determined.

Seventy-five day old female Sprague Dawley rats (weight range of 200 to 225g) were obtained from Charles River Laboratories (Portage, MI). The animals were either bilaterally ovariectomized (OVX) or exposed to a Sham surgical procedure at Charles River Laboratories, and then shipped after one week. Upon arrival, they were housed in metal hanging cages in groups of 3 or 4 per cage and had *ad libitum* access to food (calcium content approximately 0.5%) and water for one week. Room temperature was maintained at 22.2° ± 1.7° C with a minimum relative humidity of 40%. The photoperiod in the room was 12 hours light and 12 hours dark.

Dosing Regimen Tissue Collection.

After a one week acclimation period (therefore, two weeks post-OVX) daily dosing with test compound was initiated 17a-ethynodiol estradiol or the test compound were given orally, unless otherwise stated as a suspension in 1% carboxymethylcellulose or dissolved in 20% cyclodextrin. Animals were dosed daily for 4 days. Following the dosing regimen, animals were weighed and anesthetized with a ketamine: Xylazine (2.1, V/V) mixture and a blood sample was

collected by cardiac puncture. The animals were then sacrificed by asphyxiation with CO₂, the uterus was removed through a midline incision, and a wet uterine weight was determined.

Cholesterol Analysis

5

Blood samples were allowed to clot at room temperature for 2 hours, and serum was obtained following centrifugation for 10 minutes at 3000 rpm. Serum cholesterol was determined using a Boehringer Mannheim Diagnostics high performance cholesterol assay. Briefly the cholesterol was oxidized to cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide was then reacted with phenol and 4-aminophenazone in the presence of peroxidase to produce a p-quinone imine dye, which was read spectrophotometrically at 500 nm. Cholesterol concentration was then calculated against a standard curve. The entire assay was automated using a Biomek Automated Workstation.

Uterine Eosinophil Peroxidase (EPO) Assay

15

Uteri were kept at 4° C until time of enzymatic analysis. The uteri were then homogenized in 50 volumes of 50 mM Tris buffer (pH - 8.0) containing 0.005% Triton X-100. Upon addition of 0.01% hydrogen peroxide and 10 mM O-phenylenediamine (final concentrations) in Tris buffer, increase in absorbance was monitored for one minute at 450 nm. The presence of eosinophils in the uterus is an indication of estrogenic activity of a compound. The maximal velocity of a 15 second interval was determined over the initial, linear portion of the reaction curve.

20

Source of Compound

17 α -ethynodiol was obtained from Sigma Chemical Co., St. Louis, MO.

25

Influence of Formula I and II Compounds on Serum Cholesterol and Determination of Agonist/Non-Agonist Activity

30

Data presented in Table 1 below show comparative results among ovariectomized rats, rats treated with 17 α -ethynodiol (EE₂; an orally available form of estrogen), and rats treated with certain compounds of the present invention. Although EE₂ caused a decrease in serum cholesterol when orally administered at 0.1 mg/kg/day, it also exerted a stimulatory action on the uterus so that EE₂ uterine weight was substantially greater than the uterine weight of ovariectomized test animals. This uterine response to estrogen is well recognized in the art.

35

Not only did the compounds of the present invention generally reduce serum cholesterol compared to the ovariectomized control animals, but uterine weight was only minimally increased to slightly decreased with the majority of the formula compounds tested. Compared to estrogenic compounds known in the art, the benefit of serum cholesterol reduction without adversely affecting uterine weight is quite rare and desirable.

As is expressed in the below data, estrogenicity also was assessed by evaluating the adverse response of eosinophil infiltration into the uterus. The compounds of the present invention did not cause any increase in the number of eosinophils observed in the stromal layer of ovariectomized rats, while estradiol cause a substantial, expected increase in eosinophil infiltration.

40

The data presented in the Tables 1 below reflects the response of 5 to 6 rats per treatment.

Table 1

Compound	Dose mg/kg	Uterine Weight (% increase vs. OVX)	Uterine EPO (V. max)	Serum Cholesterol (% decrease vs. OVX)
EE2	0.1	86.3	116.4	81.4
Example 1	0.1	25.3	7.8	72.8

55

		1.0	9.2	3.0	51.0
5		10.0	5.9	2.1	54.6
	Example 3	0.1	32.5	4.2	51.5
		1.0	7.4	3.0	50.8
10	Example 4	0.1	10	3.3	62.6
		1.0	15.3	3.3	48.2
15	Example 5	0.1	-5.1	4.5	-9
		1.0	18.6	4.8	61.3
20	Example 6	0.1	23	4.2	-2.5
		1.0	6.4	1.8	9.9
		10.0	50.0	3.6	-11.4
25	Example 7	0.1	28.9	4.8	39.8
		1.0	31.2	6.6	65.5
		10.0	14.7	3.6	54.0
30	Example 8	0.01	10.2	2.1	50.5
		0.1	27.4	4.8	38.5
		1.0	27.2	4.8	68.0
35	Example 9	0.1	77.8	52.2	40.1
			109.1	83.1	54.7
			94.6	75.0	65.2
40	Example 11	0.1	-8.8	2.7	17.4
		1.0	3	4.2	30.9
45		10.0	-12.6	4.2	36.3
	Example 14	0.01	-0.6	2.7	24.8
50		0.1	60.0	5.4	59.5
		1.0	49.1	36.0	60.7

55 In addition to the demonstrated benefits of the compounds of the present invention, especially when compared to estradiol, the above data clearly demonstrate that compounds of Formula I and II are not estrogen mimetics. Furthermore, no deleterious toxicological effects (survival) were observed with any treatment.

Osteoporosis Test Procedure

Following the General Preparation Procedure, *infra*, the rats were treated daily for 35 days (6 rats per treatment group) and sacrificed by carbon dioxide asphyxiation on the 36th day. The 35 day time period was sufficient to allow maximal reduction in bone density measured as described herein. At the time of sacrifice, the uteri were removed, dissected free of extraneous tissue, and the fluid contents were expelled before determination of wet weight in order to confirm estrogen deficiency associated with complete ovariectomy. Uterine weight was routinely reduced about 75% in response to ovariectomy. The uteri were then placed in 10% neutral buffered formalin to allow for subsequent histological analysis.

The right femurs were excised and digitized x-rays generated and analyzed by an image analysis program (NIH image) at the distal metaphysis. The proximal aspect of the tibiae from these animals were also scanned by quantitative computed tomography.

In accordance with the above procedures, compounds of the present invention and ethynodiol diacetate (EE₂) in 20% hydroxypropyl beta-cyclodextrin were orally administered to test animals. Distal femur metaphysis data presented in Tables 2 and 3 below are the results of formula I compound treatments compared to intact and ovariectomized test animals. Results are reported as percent protection relative to ovariectomy.

Table 2

Compound/Treatment	Dose /kg	Distal Femur Metaphysis (X-ray Image Analysis-Gray Score)
EE2	0.1 mg	62.4*
Example 1	0.01 mg	14.2
	0.1 mg	49.8*
	1.0 mg	51.7*
	10.0 mg	48.2*

*P <= 0.5 two tailed Student's T Test on raw data.

In summary, ovariectomy of the test animals caused a significant reduction in femur density compared to intact, vehicle treated controls. Orally administered ethynodiol diacetate (EE₂) prevented this loss, but the risk of uterine stimulation with this treatment is ever-present.

The compounds of the present invention also prevented bone loss in a general, dose-dependent manner. Accordingly, the compounds of the present invention are useful for the treatment of post-menopausal syndrome, particularly osteoporosis.

MCF-7 Proliferation Assay

MCF-7 breast adenocarcinoma cells (ATCC HTB 22) were maintained in MEM (minimal essential medium, phenol red-free, Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (V/V), L-glutamine (2 mM), sodium pyruvate (1 mM), HEPES [(N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]]10 mM), non-essential amino acids and bovine insulin (1 ug/mL) (maintenance medium). Ten days prior to assay, MCF-7 cells were switched to maintenance medium supplemented with 10% dextran coated charcoal stripped fetal bovine serum (DCC-FBS) assay medium) in place of 10% FBS to deplete internal stores of steroids. MCF-7 cells were removed from maintenance flasks using cell dissociation medium (Ca++/Mg++ free HBSS (phenol red-free) supplemented with 10 mM HEPES and 2 mM EDTA). Cells were washed twice with assay medium and adjusted to 80,000 cells/mL. Approximately 100 mL (8,000 cells) were added to flat-bottom microculture wells (Costar 3596) and incubated at 37° C in a 5% CO₂ humidified incubator for 48 hours to allow for cell adherence and equilibration after transfer. Serial dilutions of drugs or DMSO as a diluent control were prepared in assay medium and 50 mL transferred to triplicate microcultures followed by 50 mL assay medium for a final volume of 200 mL. After an additional 48 hours at 37° C in a 5% CO₂ humidified incubator, microcultures were pulsed with tritiated thymidine (1 uCi/well) for 4 hours. Cultures were terminated by freezing at -70° C for 24 hours followed by thawing and harvesting of microcultures using a Skatron Semiautomatic Cell Harvester. Samples were counted by liquid scintillation using a Wallac BetaPlace b counter. Results in Table 3 below show the IC₅₀ for certain compounds of the present invention.

Table 3

Compound (Example Reference)	IC ₅₀ nM
1	0.2
2	100
3	3.0
4	5.0
5	1000
6	500
11	0.7
14	1

DMBA-Induced Mammary Tumor Inhibition

Estrogen-dependent mammary tumors are produced in female Sprague-Dawley rats which are purchased from Harlan Industries, Indianapolis, Indiana. At about 55 days of age, the rats receive a single oral feeding of 20 mg of 7,12-dimethylbenz[a]anthracene (DMBA). About 6 weeks after DMBA administration, the mammary glands are palpated at weekly intervals for the appearance of tumors. Whenever one or more tumors appear, the longest and shortest diameters of each tumor are measured with a metric caliper, the measurements are recorded, and that animal is selected for experimentation. An attempt is made to uniformly distribute the various sizes of tumors in the treated and control groups such that average-sized tumors are equivalently distributed between test groups. Control groups and test groups for each experiment contain 5 to 9 animals.

Compounds of Formula I are administered either through intraperitoneal injections in 2% acacia, or orally. Orally administered compounds are either dissolved or suspended in 0.2 mL corn oil. Each treatment, including acacia and corn oil control treatments, is administered once daily to each test animal. Following the initial tumor measurement and selection of test animals, tumors are measured each week by the above-mentioned method. The treatment and measurements of animals continue for 3 to 5 weeks at which time the final areas of the tumors are determined. For each compound and control treatment, the change in the mean tumor area is determined.

Uterine Fibrosis Test ProceduresTest 1

Between 3 and 20 women having uterine fibrosis are administered a compound of the present invention. The amount of compound administered is from 0.1 to 1000 mg/day, and the period of administration is 3 months.

The women are observed during the period of administration, and up to 3 months after discontinuance of administration, for effects on uterine fibrosis.

Test 2

The same procedure is used as in Test 1, except the period of administration is 6 months.

Test 3

The same procedure is used as in Test 1, except the period of administration is 1 year.

Test 4

A. Induction of fibroid tumors in guinea pig

Prolonged estrogen stimulation is used to induce leiomyomata in sexually mature female guinea pigs. Animals are dosed with estradiol 3-5 times per week by injection for 2-4 months or until tumors arise. Treatments consisting of a compound of the invention or vehicle is administered daily for 3-16 weeks and then animals are sacrificed and the uterus harvested and analyzed for tumor regression.

B Implantation of human uterine fibroid tissue in nude mice

Tissue from human leiomyomas are implanted into the peritoneal cavity and or uterine myometrium of sexually mature, castrated, female, nude mice. Exogenous estrogen are supplied to induce growth of the explanted tissue. In some cases, the harvested tumor cells are cultured *in vitro* prior to implantation. Treatment consisting of a compound of the present invention or vehicle is supplied by gastric gavage on a daily basis for 3-16 weeks and implants are removed and measured for growth or regression. At the time of sacrifice, the uterus are harvested to assess the status of the organ.

10 Test 5

A. Tissue from human uterine fibroid tumors is harvested and maintained, *in vitro*, as primary nontransformed cultures. Surgical specimens are pushed through a sterile mesh or sieve, or alternately teased apart from surrounding tissue to produce a single cell suspension. Cells are maintained in media containing 10% serum and antibiotic. Rates of growth in the presence and absence of estrogen are determined. Cells are assayed for their ability to produce complement component C3 and their response to growth factors and growth hormone. *In vitro* cultures are assessed for their proliferative response following treatment with progestins, GnRH, a compound of the present invention and vehicle. Levels of steroid hormone receptors are assessed weekly to determine whether important cell characteristics are maintained *in vitro*. Tissue from 5-25 patients are utilized.

Activity in at least one of the above tests indicates the compounds of the present invention are of potential in the treatment of uterine fibrosis.

Endometriosis Test Procedure

25 In Tests 1 and 2, effects of 14-day and 21-day administration of compounds of the present invention on the growth of explanted endometrial tissue can be examined.

Test 1

30 Twelve to thirty adult CD strain female rats are used as test animals. They are divided into three groups of equal numbers. The estrous cycle of all animals is monitored. On the day of proestrus, surgery is performed on each female. Females in each group have the left uterine horn removed, sectioned into small squares, and the squares are loosely sutured at various sites adjacent to the mesenteric blood flow. In addition, females in Group 2 have the ovaries removed.

35 On the day following surgery, animals in Groups 1 and 2 receive intraperitoneal injections of water for 14 days whereas animals in Group 3 receive intraperitoneal injections of 1.0 mg of a compound of the present invention per kilogram of body weight for the same duration. Following 14 days of treatment, each female is sacrificed and the endometrial explants, adrenals, remaining uterus, and ovaries, where applicable, are removed and prepared for histological examination. The ovaries and adrenals are weighed.

40 Test 2

45 Twelve to thirty adult CD strain female rats are used as test animals. They are divided into two equal groups. The estrous cycle of all animals is monitored. On the day of proestrus, surgery is performed on each female. Females in each group have the left uterine horn removed, sectioned into small squares, and the squares are loosely sutured at various sites adjacent to the mesenteric blood flow.

50 Approximately 50 days following surgery, animals assigned to Group 1 receive intraperitoneal injections of water for 21 days whereas animals in Group 2 receive intraperitoneal injections of 1.0 mg of a compound of the present invention per kilogram of body weight for the same duration. Following 21 days of treatment, each female is sacrificed and the endometrial explants and adrenals are removed and weighed. The explants are measured as an indication of growth. Estrous cycles are monitored.

Test 3**A. Surgical induction of endometriosis**

55 Autographs of endometrial tissue are used to induce endometriosis in rats and/or rabbits. Female animals at reproductive maturity undergo bilateral oophorectomy, and estrogen is supplied exogenously thus providing a specific and constant level of hormone. Autologous endometrial tissue is implanted in the peritoneum of 5-150 animals and

estrogen supplied to induce growth of the explanted tissue. Treatment consisting of a compound of the present invention is supplied by gastric lavage on a daily basis for 3-16 weeks, and implants are removed and measured for growth or regression. At the time of sacrifice, the intact horn of the uterus is harvested to assess status of endometrium.

5 B. Implantation of human endometrial tissue in nude mice.

Tissue from human endometrial lesions is implanted into the peritoneum of sexually mature, castrated, female, nude mice. Exogenous estrogen is supplied to induce growth of the explanted tissue. In some cases, the harvested endometrial cells are cultured *in vitro* prior to implantation. Treatment consisting of a compound of the present invention supplied by gastric gavage on a daily basis for 3-16 weeks, and implants are removed and measured for growth or regression. At the time of sacrifice, the uteri are harvested to assess the status of the intact endometrium.

Test 4

15 A Tissue from human endometrial lesions is harvested and maintained *in vitro* as primary nontransformed cultures. Surgical specimens are pushed through a sterile mesh or sieve or alternately teased apart from surrounding tissue to produce a single cell suspension. Cells are maintained in media containing 10% serum and antibiotic. Rates of growth in the presence and absence of estrogen are determined. Cells are assayed for their ability to produce complement component C3 and their response to growth factors and growth hormone. *In vitro* cultures are assessed for their proliferative response following treatment with progestins, GnRH, a compound of the invention, and vehicle. Levels of steroid hormone receptors are assessed weekly to determine whether important cell characteristics are maintained *in vitro*. Tissue from 5-25 patients is utilized.

20 Activity in any of the above assays indicates that the compounds of the present invention are useful in the treatment of endometriosis.

25 Inhibition of Aortal Smooth Cell Proliferation/Restenosis Test Procedure

Compounds of the present invention have capacity to inhibit aortal smooth cell proliferation. This can be demonstrated by using cultured smooth cells derived from rabbit aorta, proliferation being determined by the measurement 30 of DNA synthesis. Cells are obtained by explant method as described in Ross, J. of Cell Bio. 50: 172 (1971). Cells are plated in 96 well microtiter plates for five days. The cultures become confluent and growth arrested. The cells are then transferred to Dulbecco's Modified Eagle's Medium (DMEM) containing 0.5 - 2% platelet poor plasma, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mC/ml ³H-thymidine, 20 ng/ml platelet-derived growth factor, and varying concentrations of the present compounds. Stock solution of the compounds is prepared in dimethyl sulfoxide and then diluted to appropriate concentration (0.01 - 30 mM) in the above assay medium. Cells are then incubated at 37° C. for 24 hours under 5% CO₂/95% air. At the end of 24 hours, the cells are fixed in methanol. ³H thymidine incorporation in DNA is then determined by scintillation counting as described in Bonin, *et al.*, Exp. Cell Res. 181: 475-482 (1989).

40 Inhibition of aortal smooth muscle cell proliferation by the compounds of the present invention are further demonstrated by determining their effects on exponentially growing cells. Smooth muscle cells from rabbit aortae are seeded in 12 well tissue culture plates in DMEM containing 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. After 24 hours, the cells are attached and the medium is replaced with DMEM containing 10% serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and desired concentrations of the compounds. Cells are allowed to grow for four days. Cells are treated with trypsin and the number of cells in each culture 45 is determined by counting using a ZM-Coulter counter.

Activity in the above tests indicates that the compounds of the present invention are of potential in the treatment of restenosis.

The present invention also provides a method of alleviating post-menopausal syndrome in women which comprises the aforementioned method using compounds of Formula I and further comprises administering to a woman an effective 50 amount of estrogen or progestin. These treatments are particularly useful for treating osteoporosis and lowering serum cholesterol because the patient will receive the benefits of each pharmaceutical agent while the compounds of the present invention would inhibit undesirable side-effects of estrogen and progestin. Activity of these combination treatments in any of the post-menopausal tests, *infra*, indicates that the combination treatments are useful for alleviating the symptoms of post-menopausal symptoms in women.

55 Various forms of estrogen and progestin are commercially available. Estrogen-based agents include, for example, ethynodiol diacetate (0.01 - 0.03 mg/day), mestranol (0.05 - 0.15 mg/day), and conjugated estrogenic hormones such as Premarin® (Wyeth-Ayerst, 0.3 - 2.5 mg/day). Progestin-based agents include, for example, medroxyprogesterone such as Provera® (Upjohn, 2.5 - 10 mg/day), norethynodrel (1.0 - 10.0 mg/day), and nonethindrone (0.5 - 2.0 mg/day). A

preferred estrogen-based compound is Premarin, and norethynodrel and norethindrone are preferred progestin-based agents.

The method of administration of each estrogen- and progestin-based agent is consistent with that which is known in the art. For the majority of the methods of the present invention, compounds of Formula I and II are administered continuously, from 1 to 3 times daily. However, cyclical therapy may especially be useful in the treatment of endometriosis or may be used acutely during painful attacks of the disease. In the case of restenosis, therapy may be limited to short (1-6 months) intervals following medical procedures such as angioplasty.

As used herein, the term "effective amount" means an amount of compound of the present invention which is capable of alleviating the symptoms of the various pathological conditions herein described. The specific dose of a compound administered according to this invention will, of course, be determined by the particular circumstances surrounding the case including, for example, the compound administered, the route of administration, the state of being of the patient, and the pathological condition being treated. A typical daily dose will contain a nontoxic dosage level of from about 5 mg to about 600 mg/day of a compound of the present invention. Preferred daily doses generally will be from about 15 mg to about 80 mg/day.

The compounds of this invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These compounds preferably are formulated prior to administration, the selection of which will be decided by the attending physician. Thus, another aspect of the present invention is a pharmaceutical composition comprising an effective amount of a compound of Formula I or II, or a pharmaceutically acceptable salt thereof, optionally containing an effective amount of estrogen or progestin, and a pharmaceutically acceptable carrier, diluent, or excipient.

The total active ingredients in such formulations comprises from 0.1% to 99.9% by weight of the formulation. By "pharmaceutically acceptable" it is meant the carrier, diluent, excipients and salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.

Pharmaceutical formulations of the present invention can be prepared by procedures known in the art using well known and readily available ingredients. For example, the compounds of formula I and II, with or without an estrogen or progestin compound, can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl-pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid polyethyl glycols.

The compounds also can be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for example, by intramuscular, subcutaneous or intravenous routes. Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like. The formulations can be so constituted that they release the active ingredient only or preferably in a particular physiological location, possibly over a period of time. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.

Compounds of formula I and II, alone or in combination with a pharmaceutical agent of the present invention, generally will be administered in a convenient formulation. The following formulation examples only are illustrative and are not intended to limit the scope of the present invention.

Formulations

In the formulations which follow, "active ingredient" means a compound of formula I or II, or a salt or solvate thereof.

Formulation 1 Gelatin Capsules

Hard gelatin capsules are prepared using the following

Ingredient	Quantity (mg/capsule)
Active ingredient	0.1 - 1000
Starch, NF	0 - 650
Starch flowable powder	0 - 650
Silicone fluid 350 centistokes	0 - 15

EP 0 761 669 A2

The formulation above may be changed in compliance with the reasonable variations provided
A tablet formulation is prepared using the ingredients below:

Formulation 2 Tablets

5

10

Ingredient	Quantity (mg/tablet)
Active ingredient	2.5 - 1000
Cellulose, microcrystalline	200 - 650
Silicon dioxide, fumed	10 - 650
Stearate acid	5 - 15

15 The components are blended and compressed to form tablets.

15 Alternatively, tablets each containing 2.5 - 1000 mg of active ingredient are made up as follows

Formulation 3: Tablets

20

25

Ingredient	Quantity (mg/tablet)
Active ingredient	25 - 1000
Starch	45
Cellulose, microcrystalline	35
Polyvinylpyrrolidone (as 10% solution in water)	4
Sodium carboxymethyl cellulose	4.5
Magnesium stearate	0.5
Talc	1

30

The active ingredient, starch, and cellulose are passed through a No 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No 14 mesh U.S. sieve. The granules so produced are dried at 50°-60° C and passed through a No 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets

35

Suspensions each containing 0.1 - 1000 mg of medicament per 5 ml dose are made as follows:

Formulation 4: Suspensions

40

45

Ingredient	Quantity (mg/5 ml)
Active ingredient	0.1 - 1000 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 mg
Benzoic acid solution	0.10 mL
Flavor	q.v
Color	q.v
Purified water to	5 mL

50

The medicament is passed through a No 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.

An aerosol solution is prepared containing the following ingredients.

55

Formulation 5 Aerosol

Ingredient	Quantity (% by weight)
Active ingredient	0.25
Ethanol	25.75
Propellant 22 (Chlorodifluoromethane)	70.00

10 The active ingredient is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to 30° C., and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remaining propellant. The valve units are then fitted to the container.

Suppositories are prepared as follows:

Formulation 6: Suppositories

Ingredient	Quantity (mg/suppository)
Active ingredient	250
Saturated fatty acid glycerides	2,000

20 The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimal necessary heat. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

An intravenous formulation is prepared as follows.

Formulation 7: Intravenous Solution

30

Ingredient	Quantity
Active ingredient	50 mg
Isotonic saline	1,000 mL

35

The solution of the above ingredients is intravenously administered to a patient at a rate of about 1 mL per minute.

Formulation 8: Combination Capsule I

40

	Ingredient	Quantity (mg/capsule)
	Active ingredient	50
45	Premarin	1
	Avicel pH 101	50
50	Starch 1500	117.50
	Silicon Oil	2
	Tween 80	0.50
55	Cab-O-Sil	0.25

Formulation 9: Combination Capsule II

5

Ingredient	Quantity (mg/capsule)
Active ingredient	50
Norethynodrel	5
Avicel pH 101	82.50
Starch 1500	90
Silicon Oil	2
Tween 80	0.50

10

Formulation 10: Combination Tablet

15

20

Ingredient	Quantity (mg/capsule)
Active ingredient	50
Premarin	1
Com Starch NF	50
Povidone, K29-32	6
Avicel pH 101	41.50
Avicel pH 102	136.50
Crospovidone XL10	2.50
Magnesium Stearate	0.50
Cab-O-Sil	0.50

25

The compounds of the present invention may contain one or more assymetric centers, and therefore can exist as a mixture of isomers, or as individual isomers. Either a mixture or individual isomers will be useful for the purposes of the present invention, and can be so employed

Claims

35


1. A compound of formula I or II.


40

45

50

55





wherein

X is -O-, -S-, or -NR⁵;
Y is -O-, -S-, -CH₂-, -CH₂CH₂-, -CH=CH-, or -NR⁵;

B is -CH₂- or -CO-,

R¹, R², and R³ are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₄-C₆ alkyl), -OSO₂CF₃, Cl, or F,

n is 1 or 2;

W is CH₂ or C=O,

R⁴ is 1-piperidinyl, 2-oxo-1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino or 1-hexamethyleneimino;

R⁵ is C₁-C₃ alkyl, -COC₆H₅, -CO(C₁-C₆ alkyl), -C(O)OC₆H₅, -C(O)O(C₁-C₆ alkyl), -SO₂(C₁-C₆ alkyl), -SO₂C₆H₅, or -SO₂CF₃; or a pharmaceutically acceptable salt thereof.

35

2. A compound according to Claim 1 which is of Formula I and wherein X is -O- and Y is -S-.
3. A compound according to Claim 1 which is of Formula II and wherein Y is -CH=CH-.
- 40 4. A compound according to any of claims 1 to 3 wherein -O-(CH₂)_n-W-R⁴ is 2-(1-piperidinyl) ethoxy.
5. A compound according to Claim 1 which is selected from the group consisting of:

45 3,9-dihydroxy-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran;

3,9-dimethoxy-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran,

3,9-bis(benzoyloxy)-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran,

50

3,9-bis(pivaloyloxy)-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran;

3,9-bis(1-butylsulfonyloxy)-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran,


55

3,9-bis(trifluoromethanesulfonyloxy)-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran,

6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran;

- 3,9-dihydroxy-6-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran;
 5
 3,9-dihydroxy-6-[4-(2-dimethylaminoethoxy)phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran,
 3,9-dihydroxy-6-[4-[2-(2-oxo-1-pyrrolidinyl)ethoxy]phenyl]-6-H-[1]benzothieno[3,2-c] [1]benzopyran,
 10
 3,9-dihydroxy-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6-H-benzofuro[3,2-c] [1]benzopyran,
 2,8-dimethoxy-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-11,12-dihydro-6H-benzo[c]phenanthrid-6-one;
 15
 2,8-dimethoxy-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6H-benzo[c]phenanthridine,
 2,8-dihydroxy-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-6H-benzo[c]phenanthridine, and
 2,8-dihydroxy-5-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-5H-benzo[b]naphtho[2,1-d]pyran

6. A process for preparing a compound of the formula



wherein


- 40
 X is -O-, -S-, or -NR⁵;
 Y is -O-, -S-, -CH₂-, -CH₂CH₂-, -CH=CH-, or -NR⁵-,
 R¹, R², and R³ are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₄-C₆ alkyl), -OSO₂CF₃, Cl, or F;
 45
 n is 1 or 2;
 W is CH₂ or C=O;
 R⁴ is 1-piperidinyl, 2-oxo-1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino,
 50
 R⁵ is C₁-C₃ alkyl, -COC₆H₅, -CO(C₁-C₆ alkyl), -C(O)OC₆H₅, -C(O)O(C₁-C₆ alkyl), -SO₂(C₁-C₆ alkyl), -SO₂C₆H₅, or -SO₂CF₃, or a pharmaceutically acceptable salt thereof, which comprises:
 (i) reacting a compound of the formula

55

5

10

15



20


wherein

 R^{1a} , R^{2a} and R^{3a} are each independently H, $-O(C_1-C_4\text{ alkyl})$, -Cl, -F, or a protected -OH;

X and Y are as defined above,

and Z^a is -OH, $-OC_6H_5$, or $-O(C_1-C_4\text{ alkyl})$, with a Grignard reagent of the formula

25



30

wherein


 G^a is $-OSi(CH_3)_3$, a protected OH capable of being selectively deprotected in the presence of R^{1a} , R^{2a} and R^{3a} , or $-(CH_2)_nWR^4$, to obtain a compound of the formula

35

40

45

50



55


(2) in the instance when G^a is $-OSi(CH_3)_3$ or a protected OH as defined, (a) treating the product of step (1) to selectively deprotect to a compound of the formula

5

10

15

20



25

30

35


40

45


50

55


and thereafter (b) alkylating this compound to a compound of the formula



(3) deprotecting any protected OH groups in R^{1a}, R^{2a}, or R^{3a} in the compound from step 1 or step 2, to obtain the compound of the formula.



7. . . A process for preparing a compound of the formula



wherein

B is -CH<sub>2</sub>- or -CO-;

Y is -O-, -S-, -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-, or -NR<sup>5</sup>-;

R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> are each independently -H, -OH, -O(C<sub>1</sub>-C<sub>4</sub> alkyl), -OCOC<sub>6</sub>H<sub>5</sub>, -OCO(C<sub>1</sub>-C<sub>6</sub> alkyl), -OSO<sub>2</sub>(C<sub>4</sub>-C<sub>6</sub> alkyl), -OSO<sub>2</sub>CF<sub>3</sub>, Cl, or F;

n is 1 or 2;

W is CH<sub>2</sub> or C=O,

R<sup>4</sup> is 1-piperidinyl, 2-oxo-1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino or 1-hexamethyleneimino;

R<sup>5</sup> is C<sub>1</sub>-C<sub>3</sub> alkyl, -COC<sub>6</sub>H<sub>5</sub>, -CO(C<sub>1</sub>-C<sub>6</sub> alkyl), -C(O)OC<sub>6</sub>H<sub>5</sub>, -C(O)O(C<sub>1</sub>-C<sub>6</sub> alkyl), -SO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), -SO<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, or -SO<sub>2</sub>CF<sub>3</sub>.


or a pharmaceutically acceptable salt thereof which comprises
 (1) alkylating a compound of the formula

5

10

15

20



wherein

25

Y is defined above, and
 each of R^{1a}, R^{2a} and R^{3a} is independently -H, -O(C₁-C₄ alkyl), -Cl, -F, or a protected -OH,

30


- (2) optionally reducing the carbonyl;
- (3) optionally dehydrogenating the product of either preceding step wherein Y is -CH₂-CH₂-;
- (4) deprotecting any protected OH groups in R^{1a}, R^{2a} and R^{3a} in the product of any of steps (1), (2), or (3); and
- (5) optionally sialifying the product of the preceding step

8. A compound of the formula

35

40

45




50

wherein

55

X is -O-, -S-, or -NR⁵-;
 Y is -O-, -S-, -CH₂-, -CH₂CH₂-, -CH=CH- or -NR⁵-,
 each of R^{1a}, R^{2a} and R^{3a} is independently -H, -O(C₁-C₄ alkyl), -Cl, -F, or a protected -OH, and
 Z is -OH, -OC₆H₅, -O(C₁-C₄ alkyl), or 4-hydroxyphenyl.

9. A compound of the formula



20 wherein

Y is -O-, -S-, -CH₂-, -CH₂CH₂-, -CH=CH- or -NR⁵-;
 each of R^{1a}, R^{2a} and R^{3a} is independently -H, -O(C₁-C₄ alkyl), -Cl, -F, or a protected -OH; and
 each of R^{1a}, R^{2a} and R^{3a} is independently -H, -O(C₁-C₄ alkyl), -Cl, -F, or a protected -OH group

25

- 10. A pharmaceutical composition comprising a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, and optionally an effective amount of estrogen or progestin, in combination with a pharmaceutically acceptable carrier, diluent, or excipient
- 30 11. A compound of formula I as claimed in Claim 1 for use in inhibiting bone loss or bone resorption
- 12. A compound of formula I as claimed in Claim 1 for use in lowering serum cholesterol levels.

35

40

45

50

55



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 761 669 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
29.10.1997 Bulletin 1997/44

(51) Int Cl. 6 C07D 495/04, C07D 311/78,
C07D 221/18, C07D 493/04,
A61K 31/35, A61K 31/435,
C07F 7/18
// (C07D495/04, 333:00,
311:00),
(C07D493/04, 311:00, 307:00)

(43) Date of publication A2:
12.03.1997 Bulletin 1997/11

(21) Application number: 96306351.6

(22) Date of filing: 02.09.1996

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE

Designated Extension States:
AL LT LV SI

(30) Priority: 08.09.1995 US 3496


(71) Applicant ELI LILLY AND COMPANY
Indianapolis, Indiana 46285 (US)

(72) Inventor Grese, Timothy Alan
Indianapolis, Indiana 46236 (US)

(74) Representative Tapping, Kenneth George et al
Lilly Industries Limited
European Patent Operations
Erl Wood Manor
Windlesham Surrey GU20 6PH (GB)


(54) Pentacyclic compounds, intermediates, processes, compositions, and methods

(57) The present invention relates to compounds of formula I and II,



I

EP 0 761 669 A3



wherein

X is -O-, -S-, or -NR⁵-;

Y is -O-, -S-, -CH₂-, -CH₂CH₂-, -CH=CH-, or -NR⁵-,

B is -CH²- or -CO-,

R¹, R², and R³ are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₄-C₆ alkyl), -OSO₂CF₃, Cl, or F,

n is 1 or 2;

W is CH₂ or C=O,

R⁴ is 1-piperidinyl, 2-oxo-1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino.

R⁵ is C₁-C₃ alkyl, -COC₆H₅, -CO(C₁-C₆ alkyl), -C(O)OC₆H₅, -C(O)O(C₁-C₆ alkyl), -SO₂(C₁-C₆ alkyl), -SO₂C₆H₅, or -SO₂CF₃;

or a pharmaceutically acceptable salt thereof.

Also provided by the present invention are intermediate compounds, processes for the preparation of compounds of Formulae I and II; and pharmaceutical methods and formulations employing the compounds of Formulae I and II.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 30 6351

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.)
A	US 3 912 740 A (ZEE-CHENG KWANG YUEN ET AL) 14 October 1975 * the whole document * ---	1,3,10	C07D495/04 C07D311/78 C07D221/18 C07D493/04 A61K31/35 A61K31/435 C07F7/18 //(C07D495/04, 333:00, 311:00), (C07D493/04, 311:00,307:00)
A	EP 0 487 930 A (NIPPON KAYAKU KK) 3 June 1992 * claims * ---	1,3,10	
A	US 2 987 398 A (EMANUEL M. BICKOFF ET AL) 6 June 1961 * the whole document * ---	1,10-12	
A	US 2 884 427 A (OLIVER H. EMERSON ET AL) 28 April 1959 * the whole document * ---	1	
A	JOURNAL OF ORGANIC CHEMISTRY, vol. 40, no. 22, 1975, EASTON US, pages 3169-3173, XP002039650 RICHARD A. CONLEY ET AL: "Thianaphthen-2-one chemistry.I. Synthesis of 6H-benzothieno[3,2-c]benzopyran-6-ones(11-thiacumestans)" * the whole document * -----	1	
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Personnel	
THE HAGUE	4 September 1997	Henry, J	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
3			

This Page Blank (uspto)